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ABSTRACT 
Dehydroepiandrosterone (DHEA) and its sulfate ester, DHEAS, together represent the most 
abundant steroid hormones in the human body. Nonetheless, their physiological significance, their 
mechanisms of action and their possible roles in human disease are not well understood. 
Highlighting the potential health significance of DHEA and DHEAS, concentrations of these 
hormones in humans typically decrease steadily with age, approaching a nadir at about the time 
many diseases of aging become markedly more prevalent.  There is growing evidence in the 
literature that a low DHEAS level, negatively correlates with the domains of sexual function in pre 
and postmenopausal women to a greater extent than testosterone levels. Biological actions of 
DHEA(S) involve neuroprotection, neurite growth, neurogenesis and neuronal survival, apoptosis, 
catecholamine synthesis and secretion, as well as anti-oxidant, anti-inflammatory and anti-
glucocorticoid effects. In addition, DHEA affects neurosteroidogenis and endorphin 
synthesis/release. We demonstrated in a model of ovariectomized rats that DHEA therapy increases 
proceptive behaviors, already after 1 week of treatment, affecting central function of sexual drive. 
In women, the analyses of clinical outcomes are far from being conclusive and many issues should 
still be addressed. Although DHEA preparations have been available in the market since the 1990s, 
there are very few definitive reports on the biological functions of this steroid, and it is still the case 
that its regulation is unclear and its mechanisms of action largely yet to be established. We 
demonstrate that one year DHEA administration at the dose of 10 mg provided a significant 
improvement in comparison with vitamin D in sexual function and in frequency of sexual 
intercourse in early postmenopausal women. Among symptomatic women, the spectrum of 
symptoms responding to DHEA requires further investigation, to define the type of sexual 
symptoms (e.g. decreased sexual function or hypoactive sexual desire disorder) and the degree of 
mood/cognitive symptoms that could be responsive to hormonal treatment. In this regard, our 
findings are promising, although they need further exploration with a larger and more representative 
sample size. 
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1. INTRODUCTION 
The growth, differentiation, normal physiology and aging of the CNS are all now recognized to be 
influenced by gonadal steroid hormones. Steroids arriving from the gonads via the circulation 
modulate the responses of the brain, affecting not only sex behavior and sexually differentiated 
stereotypical behavioral responses, but also the ability of the brain to process, store and retrieve 
sensory information.  
Dehydroepiandrosterone (DHEA) and its sulfate ester, DHEAS, together represent the most 
abundant steroid hormones in the human body. Nonetheless, their physiological significance, their 
mechanisms of action and their possible roles in human disease are not well understood. 
Highlighting the potential health significance of DHEA and DHEAS, concentrations of these 
hormones in humans typically decrease steadily with age, approaching a nadir at about the time 
many diseases of aging become markedly more prevalent. Observations such as these, coupled with 
basic and preclinical demonstrations of DHEA’s biological effects, fostered hope that restoring 
DHEA to youthful levels might, conservatively, increase well-being and, optimistically, extend life, 
protect the brain, and retard the ravages of aging. Almost from the time of their initial discovery and 
synthesis, DHEA and DHEAS were evaluated in the treatment of neuropsychiatric disorders, with 
published reports appearing as early as 1952. Large-scale enthusiasm for DHEA as a potential 
neuropsychiatric therapy languished until the late 1980s through the mid-1990s, when an expanding 
body of preclinical data plus the first adequately controlled clinical trial renewed hopes for 
therapeutic potential.  
Sexuality is determined by both intrinsic and extrinsic variables; and midlife is a multifaceted stage 
of woman’s developments, characterized by important transitions. The difference between aging 
and sex in men and women is that women, experiment a menopause transition in which the 
hormone changes will occur in a relative short period; and in men the hormonal changes occur 
gradually during a more longer period. It is important to determine whether changes in women’s 
sexual functioning during midlife are due to aging or to menopause. Recent research suggesting that 
a high proportion of men and women remain sexually active in later life refutes the beliefs of most 
of the cultures, that women become sexually retired or that sexual interest declines with age. 
Though a large attention has been given to the study of postmenopause and to the options in 
hormone replacement treatment (i.e. estrogens and progestins), relative attention and awareness has 
been focused on the activity of endogenous or exogenous androgens in women. In fact the middle 
age of women life is characterized by the coexistence of menopause and adrenopause that 
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sometimes both participate to create the androgen-deficiency syndrome. Thus, much more 
interested have been launched to the study of androgen role in the modulation of brain function in 
term of sexuality, mood, cognition and neuroaging process. In these terms, the field of inquiry into 
the neurobiological actions of DHEA and DHEAS is rapidly growing. 
The present thesis is to review briefly basic and preclinical studies of DHEA(S) biological actions 
in the brain and their supposed mechanisms of action, (2) to evaluate DHEAS specific effects on 
sexual function in vivo, and (3) the therapeutic potential of DHEA(S) in postmenopausal women 
using on measure of quality of life and sexual function. 
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2. DHEA(S ) SYNTHESIS AND METABOLISM 
Dehydroepiandrosterone, 5-androsten-3 beta-ol-17-one, is a 19 carbon steroid that is synthesized 
from cholesterol by two steroid metabolizing enzymes (1). The first, rate-limiting, and hormonally 
regulated step in the synthesis of all steroid hormones is the conversion of cholesterol into 
pregnenolone by the mitochondrial enzyme cholesterol side chain cleavage P450scc. Pregnenolone 
is converted into DHEA by the enzyme cytochrome P450c17; this single enzyme catalyzes both the 
17α-hydroxylation reaction converting pregnenolone to 17-OH pregnenolone and the 17,20-lyase 
reaction converting 17-OH pregnenolone to DHEA (2). The sulfation of DHEA into its more stable 
sulfate ester DHEAS is catalyzed by the enzyme hydroxysteroid sulfotransferase (HST, SULT2A1), 
commonly known as DHEA sulfotransferase. DHEAS can be converted back into DHEA by steroid 
sulfatase (STS).  
People with 17α-hydroxylase deficiency are characterized by sexual infantilism in phenotypic 
females (due to lack of sex steroid precursors), 46,XY disorder of sexual development (lack of 
masculinization – female infantile external genitalia, no uterus), hypertension, and hyperkalemia (3). 
P450c17 is encoded by a single gene (cyp17) and mutations can cause either 17α-hydroxylase 
deficiency or 17,20-lyase deficiency or both (3). In addition to its expression in human adrenals and 
gonads, P450c17 is also expressed in the brain (4), where it may synthesize DHEA from 
pregnenolone. There are no reported neurological problems in people with P450c17 gene mutations, 
perhaps because they obtain sufficient quantities of 17-hydroxylated steroids from their mothers 
during prenatal development. Adults with P450c17 gene mutations are not well studied and may be 
an interesting group to examine with regard to neuropsychiatric illness, although this could be 
complicated with the possible psychological effects of sexual infantilism. Mouse studies knocking 
out this gene were uninformative, as the P450c17−/− mice died by embryonic day 7 before 
gastrulation, and the cause of this early lethality is unknown (5). 
Adrenal secretion of DHEA and DHEA-S increases during adrenarche in children at the age of 6–8 
years. Maximal values of circulating DHEA-S are reached between the ages of 20 and 30 years. 
Thereafter, serum DHEA and DHEA-S levels decrease markedly (6-7). In fact, at 70 years of age, 
serum DHEA-S levels are decreased to approximately 20% of their peak values, while they can 
decrease by 95% by the age of 85–90 years. 
The marked reduction in the formation of DHEA-S by the adrenals during aging (6-7) results in a 
dramatic fall in the formation of androgens and estrogens in peripheral target tissues. 
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Transformation of the adrenal precursor steroids DHEA-S and DHEA into androgens and/or 
estrogens in peripheral target tissues depends upon the level of expression of the various 
steroidogenic and metabolizing enzymes in each cell of these tissues. This sector of endocrinology 
that focuses on the intracellular hormone formation and action has been called intracrinology (8) 
(Fig.2). This situation of a high secretion rate of adrenal precursor sex steroids in men and women 
is thus completely different from all animal models used in the laboratory, namely rats, mice, 
guinea pigs and all others (except monkeys), where the secretion of sex steroids takes place 
exclusively in the gonads (7). One explanation for the delayed progress in the field of formation of 
sex steroids in peripheral target tissues or intracrinology is the fact that the adrenals of the animal 
models usually used do not secrete significant amounts of adrenal precursor sex steroids, thus 
focusing all attention on the testes and ovaries as the exclusive sources of androgens and estrogens. 
The term intracrinology was thus coined (8) to describe the synthesis of active steroids in peripheral 
target tissues where the action is exerted in the same cells where synthesis takes place without 
release of the active steroids in the extracellular space and general circulation (8). 
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Fig1. Human steroidogenic and steroid-inactivating enzymes in peripheral intracrine tissues. 4-
DIONE, androstenedione; A-DIONE, 5-alpha-androstane-3,17-dione; ADT, androsterone; epi-ADT, 
epiandrosterone; E1, estrone; E1-S, estrone sulfate; 5-DIOL-FA, androst-5-ene-3alpha,17beta-diol 
fatty acid; 5-DIOL-S, androst-5-ene-3alpha,17beta-diol sulphate; HSD, hydroxysteroid 
dehydrogenase; TESTO, testosterone; RoDH-1, Ro dehydrogenase 1; ER, estrogen receptor; AR, 
androgen receptor; UGT2B28, uridine glucuronosyl transferase 2B28; Sult2B1, sulfotransferase 
2B1; UGT1A1, uridine glucuronosyl transferase 1A1. 
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The almost exclusive focus on the role of ovarian estrogens in women’s reproductive physiology 
has removed attention from the dramatic 70% fall in circulating DHEA which already occurs 
between the ages of 20 to 30 and 40 to 50 years In fact, since DHEA is transformed to both 
androgens and estrogens in peripheral tissues, such a fall in serum DHEA and DHEA-S explains 
why women at menopause are not only lacking estrogens but are also likely to have been deprived 
of androgens for a few years, as illustrated by the 50–60% decrease in serum ADT-G (9) (Fig. 1).  
In a recent study nine androgens and their precursors and metabolites were measured by gas 
chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry in serum 
samples from 377 healthy postmenopausal women aged 55–65 years and 47 normally cycling 30- to 
35-year-old premenopausal women. A decrease of 60% was then observed in the sum of ADT-G 
and 3α-diol-G while serum DHEA was decreased by 54% in postmenopausal compared with 
premenopausal women (8). Serum testosterone, on the other hand, did not decrease significantly 
from 0.18 ± 0.07 in premenopausal to 0.14 ± 0.07 ng/ml in postmenopausal women.  
Since the serum levels of ADT-G and 3α-diol-G in women are 70% of those found in men of the 
same age while serum testosterone in women compared with men is only about 3% (0.15 ng/ml in 
women versus 4.5 ng/ml in men), it is clear that serum testosterone is not a valid marker of 
androgenicity in women. This situation is somewhat analogous to the situation in castrated men 
where castration causes a 90–95% reduction in the concentration of serum testosterone while the 
intra-prostatic concentration of DHT as well as of serum ADT-G and 3α-diol-G are only reduced by 
50–70%  (10).  
Completion of the identification and characterization of all the human UDP-glucuronosyl 
transferases has made possible the use of the glucuronide derivatives of androgens as markers of 
androgenic activity. In fact, UGT2B7, UGT2B15 and UGT2B17 are the three enzymes responsible 
for the glucuronidation of all androgens and their metabolites in the human (11). The relatively 
simple inactivation mechanisms of androgens permits measurement of the sum of the metabolites of 
all androgens in the circulation, thus offering a precise assessment of the total androgenic activity in 
both women and men.  
While the only means of determining androgenic activity in specific tissues is the direct 
measurement of the intra-tissular concentration of the active androgens, such measurements are not 
possible in the human except under exceptional circumstances such as in samples of cancer tissue 
obtained at surgery (7-9) However, while not permitting the assessment of androgenic activity in 
specific tissues, measurement by validated mass spectrometry techniques of the glucuronide 
	   10	  
derivatives of ADT and 3α-diol permits an accurate assessment of total androgenic activity in the 
whole organism. In fact, since inactivation of the active androgens into ADT and 3α-diol and their 
subsequent glucuronidation into ADT-G and 3α-diol-G is the obligatory route of elimination of 
androgens (11-12) this approach appears to be the best means of evaluating total androgenic activity 
in individual subjects and patients. The clinician can then reliably correlate these values of 
androgenic activity with the other clinical findings.  
As mentioned above, the level of transformation of the adrenal precursor steroid DHEA into 
androgens and/or estrogens in peripheral target tissues depends upon the level of expression of the 
various steroidogenic enzymes in each cell of each of these tissues (8). This situation of a high 
secretion rate of adrenal precursor sex steroids by the adrenals in men and women is thus 
completely different from all animal models used in the laboratory, namely rats, mice, guinea pigs 
and all others (except monkeys), where the secretion of sex steroids takes place exclusively in the 
gonads and the adrenals do not secrete significant amounts of DHEA (14). 
The classical concept of androgen and estrogen secretion in women assumed that all sex steroids 
had to be transported by the general circulation following secretion by the ovaries before reaching 
the target tissues. According to this classical concept, it was erroneously believed that the active 
steroids could be measured directly in the circulation, thus providing a potentially valid measure of 
the general exposure of the whole body to sex steroids. In fact, this concept is valid only for animal 
species lower than primates but it does not apply to the human, especially in postmenopausal 
women where all estrogens and almost all androgens are made locally from DHEA in the peripheral 
tissues, which possess the enzymes required to synthesize active sex steroids. Such a local 
biosynthesis and action of androgens in target tissues eliminates the exposure of other tissues to 
androgens and thus minimizes the risks of undesirable masculinizing or other androgen-related side-
effects. The same applies to estrogens, although we feel that a reliable parameter of total estrogen 
secretion (comparable with the glucuronides identified for androgens) has yet to be determined. 
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Fig. 2 Schematic representation of the very important contribution of the precursor DHEA of 
adrenal origin to total androgenic activity in postmenopausal women with a parallel minor 
contribution of testosterone (TESTO) of ovarian and adrenal origins. By intracrine mechanisms, 
DHEA is transformed into testosterone and DHT in peripheral tissues and then into the inactive 
metabolites ADT and 3α-diol before transformation into the water soluble glucuronide derivatives 
ADT-G, 3α-diol-3 G and 3α-diol-17 G by the UGTs 2B7, 2B15 and 2B17. These water-soluble 
metabolites are then released into the general circulation where they can be measured. A very small 
proportion of the testosterone and DHT made intracellularly by the steroidogenic enzymes of the 
intracrine pathway diffuse into the circulation. The height of the colored boxes is proportional to the 
concentration of each steroid. 
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2.1 Relative DHEA(S) Concentrations in Brain vs. Plasma vs. CSF in Humans 
Higher concentrations of DHEA are found in the brain compared to plasma. In a study of ten 
postmortem human brains, DHEA concentrations were 29.4 nmol/kg in prefrontal lobe, 16.3 
nmol/kg in parietal lobe, 13.1 nmol/kg in temporal cortex, 16.9 nmol/kg in cerebellum, and 18.7 
nmol/kg in corpus callosum (15). These data were derived from nine women and one main (76–93 
years old), and it is worth noting that large individual differences in DHEA brain concentrations 
were observed, with prefrontal lobe DHEA concentrations ranging from 9.8 to 470 nmol/kg (16). 
Mean DHEA concentrations were 1.83 nM in plasma of living human subjects of similar ages, 
which results in a brain-to-plasma ratio of ~6.5 (16). Although human brain concentrations of 
DHEA are higher than plasma concentrations, cerebrospinal fluid (CSF) concentrations of DHEA 
are lower than plasma concentrations. DHEA concentrations in CSF were ~5% of those found in the 
plasma of humans (16). 
The validity of reported measurements of DHEAS and pregnenolone sulfate in the brain has 
recently been questioned (17,18). Many studies have relied on identification of parent compounds 
after separation of steroid sulfates from free steroids by organic:aqueous solvent extraction followed 
by a chemical reaction (solvolysis) to remove the sulfate. Analyses of sulfated steroids after 
extraction and solvolysis have found high concentrations of DHEAS and pregnenolone sulfate in 
rodent and human brains (19-20). Recent studies that measure intact sulfated compounds without 
deconjugation However, high DHEAS concentrations were found in two samples of human brain 
tissue using the new sample preparation method described above and gas chromatography-mass 
spectrometry (GC-MS) analysis (21). Hence, humans may indeed have high concentrations of brain 
DHEAS and older studies may turn out to be correct once verified using these newer analytic 
protocols (22,23). Studies relying solely on organic:aqueous extractions and solvolysis to measure 
DHEAS remain questionable and need to be reassessed. 
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2.2. Species Differences - Humans vs. Rodents 
Humans and rodents (rats and mice) differ in the pathways through which sex steroids are 
synthesized. Whereas the Δ4 pathway predominates with rodents, the 17,20-lyase activity of the 
human P450c17 enzyme strongly prefers the Δ5 pathway (24). Subsequent conversion of DHEA 
into androstenedione by 3β-hydroxysteroid dehydrogenase (3βHSD) is the only pathway by which 
humans produce androstenedione (25). In rodents, conversion of cholesterol to androstenedione can 
occur through two pathways – the Δ5 pathway described above and the Δ4 pathway which involves 
the conversion of pregnenolone into progesterone (by 3βHSD) and progesterone conversion into 
androstenedione through the 17-OH-progesterone intermediary. Thus, humans make DHEA (Δ5 
pathway) prior to downstream conversion into androstenedione and further metabolism into other 
sex steroids, whereas rodents go through the Δ4 pathway (predominantly) or Δ5 pathway. The 
species difference in predominant steroid pathways may partly explain species differences in 
peripheral circulating concentrations. Whereas DHEAS is the most abundant circulating steroid 
hormone in the human body (26), rats and mice (the species typically studied) have low circulating 
concentrations of DHEA(S) in the periphery (27). Unlike humans who secrete DHEA(S) from their 
adrenal glands and gonads, rats and mice can only synthesize and secrete DHEA(S) from their 
gonads, as their adrenal glands lack P450c17 (28). 
Like humans, rats and mice have higher concentrations of DHEA in the brain compared to the 
plasma (4). For example, Sprague-Dawley rats had mean DHEA concentrations of 0.08 ng/ml (0.28 
nM) in plasma, while brain concentrations of DHEA were 0.42 ng/g (1.46 nmol/kg) in anterior 
brain and 0.12 ng/g (0.42 nmol/kg) in posterior brain (4). These data are consistent with the 
hypothesis that in rodents, brain DHEA is derived mainly if not solely from local synthesis and not 
from peripheral synthesis. In human beings, brain DHEA may be derived from both local synthesis 
and peripheral synthesis. Thus, since DHEA is found in appreciable concentrations in brains of both 
human beings and rodents, rodents may indeed be a good model for studying the function of DHEA 
in the brain, but may not be an appropriate model for studying peripheral effects of these steroids. 
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3. DHEA(S) AS A NEUROSTEROID. 
Important actions in the central nervous system (CNS) were initially inferred from observations that 
DHEA and DHEAS were synthesized de novo in brain, as brain concentrations were higher than 
plasma concentrations and brain concentrations remained high after adrenalectomy and 
gonadectomy of rats (4). Indeed, they have been termed “neurosteroids” for this reason (29-30). 
DHEA and DHEAS were among the first neurosteroids identified in rat brains. Cytochrome 
P450c17 was found in a subset of neurons of embryonic rodent brains (29). P450c17 expression 
was mainly neuronal; its expression was found as early as embryonic day 9.5, and persisted in the 
CNS during embryonic development. In one study, P450c17 was not detected in the CNS in adult 
rats and mice by immunocytochemistry, raising the possibility that this enzyme, and its neurosteroid 
products, function mainly during development (31). However, another study found P450c17 in 
adult male rat hippocampus by immunohistochemical staining (31). In the hippocampus, P450c17 
was localized to pyramidal neurons in the CA1-CA3 region and to granule cells of the dentate gyrus. 
In these cells, P450c17 was localized in pre- and post-synaptic locations and in the endoplasmic 
reticulum by immunoelectron microscope analysis. While P450c17 protein was readily detected in 
the brain, the abundance of P450c17 mRNA transcripts in the embryonic mouse brain (31) or 
hippocampus of adult male rats was low, and was approximated to be 1/200th of the expression in 
the testis. 
DHEA can be synthesized in vivo in rat and frog brains. Rat brains were capable of converting 
pregnenolone into DHEA and this may be activity-dependent (32). Basal P450c17 steroidogenic 
enzyme activity was low in the hippocampus, but could be enhanced by exposing neurons to N-
methyl-D-aspartate (NMDA) (32). Similar findings have been reported for NMDA stimulation of 
pregnenolone synthesis from cholesterol in the hippocampus (33), suggesting that both P450scc and 
P450c17 are regulated by neurotransmitters. Frog brains also were found to synthesize DHEA from 
pregnenolone, and this enzymatic activity was reduced in a concentration-dependent manner by 
ketoconazole, an inhibitor of P450c17 (34). P450c17 enzymatic activity and protein expression 
were co-localized, further indicating that the enzymatic activity was due to P450c17. 
P450c17 expression has also been found in adult rat spinal cord. Immunohistochemical studies 
localized P450c17 in both neurons and glial cells in the spinal cord. Slices of spinal cord tissue 
containing P450c17 protein converted (3H)pregnenolone into (3H)DHEA, and this conversion was 
reduced by ketoconazole. Thus, the spinal cord is one region in the CNS of rodents that expresses 
P450c17 and can synthesize DHEA endogenously from a precursor (35). 
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DHEAS may be synthesized in the brain from DHEA (36). Sulfation of DHEA has been observed 
in the brains of rhesus monkeys in vivo and in human fetal brain slices in vitro (36). Conversion of 
(3H)DHEA into (3H)DHEAS was also found in incubations of brain homogenates from pons, 
hypothalamus, olfactory bulb, cortex, and striatum/hippocampus of fetal and adult Sprague-Dawley 
rats and from thalamus, frontal cortex, basal ganglia, olfactory bulb, hippocampus, brainstem, 
midbrain, occipital cortex and cerebellum of adult Wistar rats . In addition to mammals, DHEAS 
synthesis from DHEA has been observed in brain homogenates from hypothalamus and 
telencephalon but not rhombencephalon of adult European green frogs.  
Hydroxysteroid sulfotransferase (HST) or SULT2A1, also commonly referred to as DHEA 
sulfotransferase, is an enzyme that sulfonates DHEA (in addition to pregnenolone) (37). Western 
blotting and immunohistochemistry (with an antibody directed against partially purified rat liver 
HST) showed protein expression of an HST in adult Wistar rat brain (3). However, the 
characterization of this HST was not fully addressed, and hence its identity was uncertain. Other 
studies using different antibodies to purified or well-characterized proteins have confirmed the 
finding of HST in the brains of rats and frog. SULT2A1 mRNA expression has been shown in rat 
brains, thereby definitively demonstrating the presence of SULT2A1 in the brain. Future research 
on the activity and localization of newly discovered sulfotransferases, such as SULT2B and SULT4, 
may further our understanding of DHEA sulfonation in the brains of humans, rats and mice in the 
future (37). 
It is unlikely that brain DHEAS comes from the periphery because sulfated steroids are hydrophilic 
and do not readily cross the blood-brain barrier, as evidenced by low recovery (0.03%) of 
radioactively labeled DHEAS in the brains of Sprague-Dawley rats following intracardiac injection 
(154). Although, one study has found increased pregnenolone sulfate in the brains of Sprague-
Dawley rats after i.v. injection via the tail vein (325). What little steroid sulfates do enter the brain 
may occur through organic anion transporting peptides (OATP), which may work to transport 
DHEAS in both directions (13). However, steroid sulfates may egress from the brain more readily 
than they enter. The efflux clearance of (3H)DHEAS across the blood-brain barrier was determined 
to be tenfold greater than its influx (118 (µl/min-g efflux vs. 11.4 µl/min-g influx) (13). Hence, 
DHEAS is predominately transported out of the brain across the blood-brain barrier, further 
suggesting that DHEAS found in the brain is most likely due to local synthesis. 
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4. DHEA(S) MECHANISMS OF ACTION 
Steroid hormones affect gene transcription by binding to specific cytoplasmic receptors, and then 
translocating into the nucleus, or binding to receptors that are resident in the nucleus, where they 
bind to steroid responsive elements on DNA. To date, no nuclear steroid receptor with high affinity 
for either DHEA or DHEAS has been found (38-40). The mechanisms by which DHEA(S) operate 
are not fully understood (38). DHEA(S) may mediate some of its actions through conversion into 
more potent sex steroids and activation of androgen or estrogen receptors in tissue (i.e. skin, liver, 
brain) (41). In addition to DHEA(S) having effects through its sex steroid metabolites (i.e. estradiol 
and testosterone), DHEA(S) may also have effects through its more immediate metabolites, such as 
7α-hydroxy-DHEA (42). Although no unique DHEA or DHEAS nuclear steroid receptor has been 
found, DHEA and DHEAS have been found to affect receptors and to show affinity for some 
binding sites (38). 
In the brain, DHEA(S) modulates actions of the γ-aminobutyric acid type A (GABAA) receptor, the 
NMDA receptor, and the sigma subtype 1 (σ1) receptor (43-48) among others (49-51). DHEA and 
DHEAS generally act as noncompetitive antagonists at the GABAA receptor, with DHEAS having 
more potent antagonistic effects than DHEA (52-53). DHEA(S) generally acts as a positive 
allosteric modulator of the NMDA receptor, although the binding of DHEA(S) with an interaction 
site on the NMDA receptor is not well documented (43,46). DHEA(S) can potentiate NMDA 
receptor function through its actions as a σ1 receptor agonist. However, in non-hippocampal brain 
regions DHEA(S) may inhibit glutamate neurotransmission through σ receptors, since σ receptor 
agonists were shown to reduce NMDA-induced dopamine release in the striatum (54). In an 
electrophysiological study with Sprague-Dawley rats, intravenous (i.v.) administration of DHEA 
(100–500 µg/kg) potentiated the NMDA neuronal response of CA3 rat hippocampus pyramidal 
neurons in a dose-dependent manner (32). The addition of σ receptor antagonist haloperidol or σ1 
receptor antagonist N-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)-ethylamine 
monohydrochloride (NE-100), but not saline or spiperone (which has low affinity for σ receptors), 
inhibited the potentiating effect of DHEA, suggesting that DHEA can modulate the NMDA 
response through σ1 receptors (55). DHEAS potentiated the NMDA evoked release of 
(3H)norepinephrine from preloaded hippocampal slices, while the addition of σ receptor antagonists 
haloperidol or 1-(2-(3,4-dichlorophenyl)-ethyl)-4-methylpiperazine (BD1063) blocked the 
potentiating effect of DHEAS (56). Thus, DHEA(S) can modulate NMDA neurons and receptor 
activity by acting at the σ1 receptor (that is coupled to Gi/o proteins) in both in vivo and in vitro 
studies (55,56). 
	   17	  
DHEAS, but not DHEA, augments cholinergic function in several animal models (57). 
Intraperitoneal (i.p.) administration of DHEAS (25–250 µmol/kg) increased acetylcholine (ACh) 
release from hippocampal neurons in rats (58). This effect has behavioral relevance in vivo, since 
DHEAS prevented (in a dose-dependent manner) the memory impairment induced by the ACh 
receptor antagonist scopolamine in mice (59). The σ1 receptor antagonist NE-100 blocked the 
ameliorating effects of DHEAS in this model, suggesting that the modulation of the cholinergic 
system by DHEAS involves interaction with σ1 receptors (59). Long term administration (15 days) 
of the STS inhibitor p-O-(sulfamoyl)-N-tetradecanoyl tyramine (DU-14) (which inhibits the 
conversion of DHEAS to DHEA) to rats increased plasma DHEAS concentrations, decreased 
DHEA concentrations, increased hippocampal ACh release, and blocked scopolamine-induced 
amnesia (60). 
Additional intracellular sites where DHEA may act have also been described. DHEA may interact 
directly with certain cytoskeleton components or novel membrane receptors. DHEA was found to 
bind to microtubule-associated protein (MAP) 2C with strong affinity (61). MAP2C, which is 
expressed at early development stages, was found in adult retina and olfactory bulb, which are 
tissues in which neurogenesis persists in the adult (61). Intriguing leads are emerging for possible 
DHEA receptor sites in the periphery that may also exist in the central nervous system. A DHEA 
receptor was found on endothelial cell plasma membranes and it was coupled to endothelial nitric-
oxide synthase (eNOS) activity through Gi/o proteins Gαi2 and Gαi3 (62). DHEA(S) may also have 
actions at other receptors, including the peroxisome proliferator-activated receptor α (PPARα), 
pregnane X receptor, constitutive androstanol receptor, and estrogen receptor β (63-65).  
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Mechanisms of action of DHEA and DHEAS in neurons. This cartoon summarizes many of the actions of DHEA and 
DHEAS described in detail in the text. DHEA and DHEAS have inhibitory effects (red blocking arrow) at the GABAA 
receptor (section 6 and 7.1). DHEA and DHEAS act as agonists (green arrow) at the σ1 receptor (section 6 and 7.1), 
which subsequently may activate the NMDA receptor. DHEA inhibits Ca2+ influx (red blocking arrow) into the 
mitochondria (section 7.1). DHEA influences embryonic neurite growth through stimulation (green arrow) of the 
NMDA receptor (section 7.2). DHEA increases (green arrow) kinase activity of Akt and decreases apoptosis, while 
DHEAS decreases (red blocking arrow) Akt and increases apoptosis (section 7.4). DHEAS increases (green arrows) TH 
mRNA and TH protein abundance (section 7.5) leading to increased catecholamine synthesis. DHEA and DHEAS 
stimulate (green arrows) actin depolymerization and submembrane actin filament disassembly and (green arrows), 
increasing secretion of catecholamines (“da” and “ne”) from secretory vesicles (section 7.5). DHEA and DHEAS inhibit 
(red blocking arrow) reactive oxygen species (ROS) activation of transcription mediated by NF-κB (section 7.6 and 7.7). 
DHEA inhibits (red blocking arrow) nuclear translocation of the glucocorticoid receptor (GR) (section 7.8). 
Mechanisms of action not pictured in this graph are: alterations of brain derived neurotrophic factor (BDNF) synthesis, 
inhibition of stress-activated protein kinase 3 (SAPK3) translocation, and inhibition of 11β-hydroxysteroid 
dehydrogenase type 1 (11β-HSDl) activity. Abbreviations: σ1, sigma 1 receptor; Akt, serine-threonine protein kinase 
Akt; Ca2+, calcium; da, dopamine; GABAA, γ-aminobutyric acid type A receptor; GR, glucocorticoid receptor; ne, 
norepinephrine; NF-κB, nuclear factor kappa B; NMDA, N-methyl-D-aspartate receptor; ROS, reactive oxygen species; 
TH, tyrosine hydroxylase. 
 
 
	   19	  
5. NEUROBIOGICAL ACTION OF DHEA WITH POTENTIAL RELEVANCE TO 
SEXUAL FUNCTION: EXPERIMENTAL FINDINGS 
Neurobiogical action of DHEA involve directy DHEAS, DHEA and its more immediate 
metabolites (e.g., 7α-hydroxy-DHEA) in the brain but they are also due to conversion of DHEA(S) 
into sex steroids (estradiol, testosterone, DHT, 3alpha-DIOL, 3Beta-DIOL). Neurobiological 
actions of estradiol and testosterone are well established (66-69), less characterized are the  function 
attributable directly to DHEA and DHEAS. These major biological actions of DHEA(S) involve 
neuroprotection, neurite growth, neurogenesis and neuronal survival, apoptosis, catecholamine 
synthesis and secretion, as well as anti-oxidant, anti-inflammatory and anti-glucocorticoid effects. 
In addition, DHEA affects neurosteroidogenis and endorphin synthesis/release 
5.1 DHEA and catecholamine synthesis/secretion 
DHEA(S) influence catecholamine synthesis and secretion (70). DHEAS was protective against the 
neurotoxin MPP+ (which inhibits catecholamine synthesis and triggers cell death) in rat cerebellar 
granule cell cultures. In an in vivo study of long-term DHEA treatment, obese and lean female 
Zucker rats were fed chow containing 0.6% DHEA for 28 days (71). Lean rats had higher 
norepinephrine (NE) in the lateral hypothalamus but lower NE in the paraventricular nucleus (PVN) 
of the hypothalamus compared to lean rats fed the control diet (71). There were no differences 
among obese Zucker rats in NE, serotonin (5HT), and serotonin metabolite 5-hydroxyindole-3-
acetic acid (5-HIAA) in the hypothalamus (71). In another study, obese female Zucker rats treated 
with a large, acute i.p. injection of DHEA (200 mg/kg) had increased concentrations of dopamine 
(DA), 5HT, and 5-HIAA, and decreased concentrations of NE and epinephrine (EPI) in the 
paraventricular nucleus compared to controls that received oil vehicle (72). DHEA treatment had no 
effect on neurotransmitter concentrations in the lateral hypothalamus or ventromedial hypothalamus 
(72). These in vivo studies suggest that the duration and/or dose of DHEA treatment may be 
important and that DHEA may have different effects on different parts of the hypothalamus. In vitro, 
DHEAS (10−8 M and 10−6 M) has been found to stimulate dopamine release from rat 
hypothalamic cells in primary cultures (73). 
DHEA(S) affects proliferation of catecholamine-producing adrenomedullary chromaffin cells. 
Although DHEA and DHEAS do not induce proliferation by themselves, they may modulate 
proliferation induced by growth factors and do so in an age-dependent manner. In bovine 
chromaffin cells from young animals, DHEA decreased cell proliferation induced by insulin-like 
growth factor-II (IGF-II), but had no effect on proliferation induced by basic fibroblast growth 
	   20	  
factor (bFGF) (74). In another study, DHEA decreased cell proliferation induced by leukemia 
inhibiting factor (LIF) in bovine chromaffin cells from young animals (75). In bovine chromaffin 
cells from adult animals, DHEA decreased cell proliferation induced by epidermal growth factor 
(EGF) (75). DHEAS had no effect on LIF-induced proliferation of cells from young animals, but 
high micromolar concentrations of DHEAS enhanced EGF-induced proliferation of cells from 
adults (75). The effects of DHEA and DHEAS were not due to downstream metabolism into sex 
steroids since neither the estrogen receptor antagonist ICI 182,780 nor the androgen receptor 
antagonist flutamide affected chromaffin cell proliferation (75). Thus, local production of DHEA 
and DHEAS in the adrenal cortex can influence proliferation of chromaffin cells, and may have 
similar effects on catecholamine-producing neurons in the brain. 
DHEA and DHEAS stimulate secretion of catecholamines from rat pheochromocytoma PC12 cells 
and are involved in inhibition of neuronal proliferation and promotion of differentiation of adrenal 
medullary cells to a more neuroendocrine phenotype. Administration of nerve growth factor (NGF) 
induced PC12 cells to differentiate into a neuronal phenotype, while administration of DHEA alone 
had no effect (76). PC12 cells incubated with both NGF and DHEA had lower survival and less 
neurite outgrowth than cells incubated with NGF alone in serum-free medium (76). NGF dose-
dependently induced phosphorylation of extracellular signal-regulated kinases (ERK)1/2, which 
distinguished proliferation from differentiation processes, and this ERK1/2 phosphorylation was 
inhibited by DHEA (76-77). Furthermore, DHEA stimulated dopamine release from NGF-treated 
cells, while neither NGF nor DHEA alone had an effect on dopamine release (77). Another study 
compared the stimulatory effects of DHEA and DHEAS on catecholamine synthesis. The effect of 
DHEA was faster than that of DHEAS; whereas the effect of DHEA peaked at 10 min, the effect of 
DHEAS peaked at 30 min (58). In addition to stimulating secretion, DHEAS (but not DHEA) also 
stimulated catecholamine production. DHEAS increased tyrosine hydroxylase (TH) protein 
abundance in PC12 cells after four hours of stimulation, and also increased TH mRNA abundance 
in PC12 cells after only two hours of stimulation (58). These data suggest that DHEA and DHEAS 
function differently, and that DHEAS may directly affect TH gene transcription. Experiments to 
determine if DHEA increases TH gene transcription directly have not yet been reported. 
DHEA and DHEAS have non-transcriptional effects on catecholamine secretion. DHEA and 
DHEAS have been found to stimulate actin depolymerization and submembrane actin filament 
disassembly, a fast-response cellular system regulating trafficking of catecholamine vesicles (78). 
An actin meshwork inhibits catecholamine secretory vesicles from reaching exocytosis sites. By 
decreasing this actin meshwork, DHEA and DHEAS increase the ability of catecholamines to be 
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secreted from secretory vesicles. Addition of DHEA and DHEAS to PC12 cells induced actin 
depolymerization, as measured by the ratio of G-monomeric to total cellular actin, an established 
marker of actin cytoskeleton dynamics (78). When PC12 cells were exposed to phallacidin, an actin 
filament stabilizer, the stimulatory effect of DHEA and DHEAS on both dopamine and 
norepinephrine secretion was prevented (78). These studies show that DHEA and DHEAS exert a 
direct effect on PC-12 cells (a model of chromaffin cells), and thus, provide in vitro evidence of 
how the zona reticularis and the adrenal medulla may be interacting in vivo. These findings also 
raise the possibility that DHEA and DHEAS could increase catecholamine production and release 
in the brain. 
5.2 DHEA allopregnanolone and beta-endorphin 
Allopregnanolone is a 3-α, 5-α reduced metabolite of Progesterone (79), and its major sources are 
the gonads and adrenal cortex, and, to a lesser extent, the CNS (79). Allopregnanolone acts as an 
agonist of GABAA receptor, modulating stress, mood, and behavior. Gonadal steroids may 
modulate allopregnanolone levels, as suggested by several experimental studies on animal models. 
In fact, female rats show significantly higher hippocampal allopregnanolone concentrations on the 
morning and afternoon of proestrous than at diestrous or estrous, reaching the lowest levels at 
estrous. Moreover, ovariectomy determines an increased adrenal allopregnanolone content and a 
reduction in allopregnanolone levels in brain and serum; this may be due to an estrogen-mediated 
enzymatic induction in the synthesis of allopregnanolone (79-81). 
β-endorphin is the most important and biologically active endogenous opioid peptide; it has 
behavioral, analgesic, thermoregulatory, and neuroendocrine properties. A decrease in central and 
peripheral β-EP levels in ovariectomized rats and in circulating β-EP levels in postmenopausal 
women has been shown (82) 
Dehydroepiandrosterone administration induces an increase in β-EP content in anterior and 
neurointermediate pituitary and hippocampus in a dose-dependent manner. High-dose DHEA 
administration induces an increase in β-EP circulating levels to those observed in fertile animals 
and an even greater increase in the hypothalamus. Comparing these results with those assessed 
administering E2 in ovx rats, we can observe several similarities. In all the examined organs, the 
effect of DHEA on β-EP levels closely reflects that of E2 valerate, with the exception of the 
neurointermediate pituitary, where DHEA induces a lower increase in β-EP. 
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Dehydroepiandrosterone administration induces an increase in allopregnanolone content in the 
hypothalamus, anterior pituitary, serum, and hippocampus, where DHEA administration restores 
allopregnanolone levels to those observed in fertile rats. Similar data have been observed at the 
central level when administering E2 valerate in ovx rats. However, DHEA does not determine a 
decrease in allopregnanolone adrenal content, as observed with E2. Moreover, the serum 
allopregnanolone levels reached in response to DHEA therapy are lower than those obtained with 
E2 administration (83) 
The mechanisms of action of DHEA are not clear. Part of the effects of DHEA depends on its 
conversion to estrogens and androgens and on the recruitment of their receptors. In fact, at the 
vascular level, a reduction of atherosclerotic lesions by DHEA in rabbits was reported, partially 
through conversion to estrogens. However, there is evidence that DHEA may have a specific 
receptor. This has been demonstrated in blood vessels, where DHEA binds with high affinity to 
nonhuman endothelial cell membranes without being displaced by structurally related steroids. 
The present data seem to indicate that the effect of DHEA administration may not be entirely 
ascribed to the conversion in estrogenic metabolites. In fact, the E2 levels reached in DHEA-treated 
ovx animals were not significantly different from those observed in untreated ovx animals and 
significantly lower than those obtained in ovx animals in response to E2 valerate administration. 
Similar levels of β-EP and allopregnanolone, obtained in various organs, were observed in response 
to the two different therapies. Therefore, DHEA may act directly or through its local metabolites on 
neurosteroidogenesis and the opioidergic pathway. (83) 
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6. EFFECT OF DHEA THERAPY ON SEXUAL FUNCTION USING AN IN-VIVO MODEL 
The field of behavioural pharmacology is showing an increasing interest in female rat sexual 
behaviour as a model for evaluating drug actions and steroid interference. Endogenous sex steroids 
modify female sexual behaviour in rats. Fertile animals during the estrous phase show normal level 
of sexual receptivity, which is abolished by ovariectomy and it can be partially restored by the 
subcutaneous injections of Estradiol Benzoate (EB) and Progesterone (P) (84). Sex steroids 
influence the neurobiology of sexual function, acting directly on their receptors at nuclear and 
membrane level or indirectly throughout their effects on neuropeptides (oxytocin, beta-endorphin, 
ecc.), neurotransmitters (dopamine, serotonin) and neurosteroid metabolism (mainly 
allopregnanolone) (85-86). 
Sexual behaviour in the female rat is characterized by both receptive and proceptive 
behaviours (87). Receptive behaviour consists in a reflexive posture, called lordosis, which 
represents the female readiness to allow copulation (87). Proceptive behaviours, including hops, 
darts and ear-wigglins, are exhibited by a sexually receptive female to arouse male sexual interest  
(88). Consequently they are considered appetitive behaviours, while lordosis represents the 
consummatory aspect of female sexual behavior (89). Sexual motivation of female rats can be also 
assessed by evaluating their preference for a sexually active male versus a sexually receptive female, 
during the partner preference test (90,91). In addition, if the mating occurs in a laboratory condition 
which allows the female to enter and exit from the male’s compartment, the estrous female will 
approach and withdraw from the male, controlling hence the number and the timing of sexual 
contacts (i.e. mount, intromission and ejaculation). This pattern, known as paced mating behaviour 
is thought to be influenced by sexual motivation besides to sensory discrimination between the 
different types of sexual stimulation (mount, intromission and ejaculation) (92).  
In the present study, we evaluated the influence of DHEA administration on receptive and 
proceptive components of female rat sexual behaviour and whether the co-administration of 
estrogens might enhance sexual response in a model of ovariectomized rats. 
6.1 Methods 
Animals 
Adult female Sprague-Dawley rats weighing 200-250 g were obtained from Charles River 
Laboratories (Calco, LC, Italy). They were housed two per cage and maintained in standard 
conditions at 22±1°C and 55-60% humidity. A 12-h reversed light/dark cycle was employed to 
facilitate behavioural testing during the normally active (dark) phase of the cycle. Commercial rat 
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pellets and water were freely available. After a week of adaptation, all rats were bilaterally 
ovariectomized under ketamine hydrochloride (Ketavet 100®, Farmaceutici Gellini Spa, Italy) plus 
xylazine hydrochloride (Rompun®, Bayer, Germany) anesthesia, using standard surgical procedures. 
Sexually experienced Sprague Dawley male rats, weighing approximately 350-400 g, were used as 
stimulus animals in the behavioural tests. 
Animal care, maintenance and surgery were conducted in accordance with the Italian law (D.L. n. 
116/1992) and European legislation (EEC n. 86/609). The experimental design and procedures 
received the approval of the Bioethical Committee of the Italian Institute of Health.  
 Treatments 
Treatments were started approximately 3 weeks after ovariectomy to allow a complete recovery 
from surgery. Animals were divided in 6 groups and submitted to the following treatments:  
1) Estradiol Benzoate (Estradiol benzoate, Sigma-Aldrich, Milan, Italy) (EB) 10 µg/rat 
subcutaneously (s.c.) injected 48 h before the behavioural test;  
2) Estradiol Benzoate (EB) 3 µg/rat s.c. injected 48 h prior to behavioural test;  
3) DHEA (dehydroepiandrosterone, Sigma-Aldrich, Milan, Italy) 0.5 mg/kg by oral gavage (p.os) 
daily for 6 weeks; 
4) DHEA 5 mg/kg p.os daily for 6 weeks;  
5) EB 3 µg /rat s.c. 48 h prior to behavioural test plus DHEA dosed at 0.5 mg/kg p.os daily for 6 
weeks;  
6) EB 3 µg/rat 48 h prior to behavioral test plus DHEA dosed at 5 mg/kg p.os daily for 6 weeks.  
All the females were s.c. injected  with 500 µg of progesterone (Prontogest, AMSA) 4 h before the 
tests.  Hormones were delivered in a peanut oil vehicle.  DHEA was solubilised in Tween 80 (10%) 
and water and administered  in the volume of 5 ml/kg.  
 Sexual behaviour testing 
1) Receptivity test 
The test was conducted in a clear Plexiglas arena (70×35×40 cm high), where a male rat was placed 
for a 5-min period and was allowed two intromissions with a stimulus non-experimental female to 
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ensure his sexual vigor. Thereafter, an experimental female rat was placed in the arena with the 
male. The test ended when the female received 10 mounts with or without intromission. The 
lordosis response was scored on a four-point scale (0-3) as described (93). For each rat a lordosis 
quotient (LQ) was calculated as the number of lordosis responses (scores of 2 or 3) divided by the 
total number of mounts multiplied by 100. During the test the number of proceptive behaviours 
(hops-darts, ear-wigglings, crawlings, approach and withdrawal from the male and sniffings) and 
rejective behaviours exhibited per minute were recorded. The behavioural parameters were scored 
by observers unaware of the pharmacological treatments. 
 2) Partner preference test 
 After 5 weeks of treatment the partner preference test, performed according to Ågmo et al. (94), 
was used to evaluate sexual motivation in a no-contact condition. The apparatus consisted of an 
open field arena (100×50×40 cm high) with two round cages made of wire meshing (16 cm 
diameter, 40 cm high) diagonally positioned at the opposite corners of the arena. In the two cages a 
sexually active male and a female rat were individually placed as stimulus animals. A virtual area 
near to each animal cage was defined as the incentive zone: the sexual incentive area near to the 
male and the social incentive area near to the female. In these conditions it was allowed the 
transmission of visual, olfactory and auditory cues but it was avoided mating. Experimental females 
were individually placed in the centre of arena for a 5-min adaptation period at the presence of the 
stimulus animals and thereafter tested for 10 min. The number of visits to the male and the female 
as well as the time spent near each stimulus animal were recorded. The measure of sexual 
motivation is expressed by a preference score that is the ratio between the time spent in the sexual 
incentive area versus the total time spent in the two incentive areas (94).   
 3) Paced mating behaviour  
After 6 weeks of treatment the experimental female rats were tested for paced mating behaviour 
according to the procedure described by Clark et al. (95). The apparatus consisted in a plexiglas 
arena (80×49×40 cm high) divided into three equal compartments by two clear plexiglas partitions 
(48.5×39.5 cm high) with holes (5 cm in diameter, placed 1.25 cm from the side and bottom edges) 
in the bottom corners. The small diameter of the holes enabled the female rat to enter and exit from 
the male compartment, while not allowing the access of male rat to the female’s compartment. Two 
opaque partitions (48.5×39.5 cm high), covering the holes in the plexiglas ones, were used to avoid 
the female rat and the males to see one another, when they were not being tested. 
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 The mating test started by placing the experimental female in the central compartment and a 
stimulus male rat in each of the two side chambers. The female rat was allowed to access to a single 
male rat through the hole of the clear plexiglas partition, after the removal of the opaque divider. 
The mating test ended when the female received 10 mounts with intromission. If ejaculation 
occurred, she was allowed to leave the male rat’s compartment and then return. Thereafter the 
female was confined in the central compartment replacing the opaque partition. To complete the test 
the female rat was permitted to access to the second male rat. Paced mating test was terminated: (i) 
if the female returned to the stimulus male rat, following the 10th intromission; (ii) if the female 
received no intromission within the first 15 min from the beginning of the test; (iii) when the 
interval between two intromissions was longer than 30 min. During the test the following 
parameters of sexual behaviour were registered or calculated: a) the contact-return latency, that is 
the time between the female’s exit from male’s compartment following each type of sexual 
stimulation (mount, intromission, ejaculation) and her return; b) the percentage of exits, that is the 
number of times the female rat left the male’s compartment, following each type of stimulation. 
 
Biochemical assays 
Following the conclusion of all behavioural experiments, specifically 24 h after the paced mating 
test, female rats were sacrificed by decapitation and trunk blood collected. Brains and adrenal 
glands were removed for the subsequent biochemical analysis. From the brains the following areas 
were isolated: hypothalamus, hippocampus, anterior pituitary, neurointermediate lobe, frontal and 
parietal cortex. 
 All hormonal determinations were carried out during the same assay. Plasma DHEA, 
Progesterone (P), Estradiol (E2) Testosterone (T) concentrations were determined using 
commercially available radioimmunoassays kits (Radim, Pomezia, Rome, Italy). The intra-assay 
and inter-assay coefficients of variation (CV) and the sensitivity of the assay were: 7.8 and 8.3% 
and 0.02 ng/ml for DHEA, 8,9% and 0,03 ng/ml for T, 11.7% and 0.12 ng/ml for P, 8.5% and 4.7 
pg/ml for E2, respectively. Serum corticosterone (ICN Biomedicals Inc., Irvine, CA, USA) was 
assayed by radioimmunoassay using trade kits. For corticosterone the assay sensitivity was 25 
pg/ml and the intra- and inter-assay coefficients of variation were 5.8% and 7.5% respectively. 
 
Allopregnanolone assay 
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The supernatant of tissue homogenates and serum was passed through a C-18 Sep-Pak cartridge, 
previously equilibrated with homogenizing buffer. The cartridge was sequentially washed with 
homogenizing buffer, 50% aqueous methanol, and the unconjugated steroid fraction was eluted with 
absolute methanol and brought to dryness under nitrogen. Analytical grade solvents were purchased 
from Merck (Darmstadt, Germany); C-18 Sep-Pak cartridge were obtained form Waters 
Corporation (Milford, USA). Allopregnanolone contents were measured by a radioimmunoassay 
method, using an antiserum kindly provided by Dr. RH Purdy (San Diego, CA, USA). The 
sensitivity of this assay was 20 pg/mL, the recovery after extraction and chromatography was 
86.51±2.7% (mean ± SEM), and the intra- and inter-assay coefficient of variation was 7% and 9%, 
respectively. Allopregnanolone levels were expressed in pg/mg of tissue in each tissue and in pg/ml 
in serum. 
 
β-Endorphin assay 
The supernatant of tissue homogenates and plasma were passed through a C-18 Sep-Pak cartridge, 
previously equilibrated with 50% aqueous methanol, and the unconjugated fraction was eluted with 
absolute methanol and brought to dryness under vacuum. β-endorphin levels were measured by a 
previously described specific radioimmunoassay (83), using camel β-endorphin as standard (Sigma 
Chemicals, St. Louis, MO, USA). The antiserum was used at the final dilution of 1:130.000. 
Analytical grade solvents were purchased from Merck (Darmstadt, Germany); C-18 Sep-Pak 
cartridges were obtained from Waters Corporation (Milford, USA). The sensitivity of this assay was 
10 pg/ml, the recovery following acetic acid extraction and chromatography corresponded to 
85±11% of the total amount, and the intra- and inter-assay coefficients of variation were 6% and 
8%, respectively. β-endorphin levels were expressed in ng/organ (hypothalamus, hippocampus and 
neurointermediate lobe) or ng/mg tissue (frontal and parietal cortex) and in ng/ml in plasm 
 
 
Statistical Analysis 
Behavioral and hormonal data, reported as mean ± SEM, were analyzed using GraphPad Prism 
Software, version 5.0 for Windows (GraphPad Software, San Diego, CA, USA). One-way analysis 
of variance (ANOVA) with Newman–Keuls test for post-hoc comparisons was performed between 
individual treatment groups. Values of  P < 0.05 indicate significant differences among groups. 
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6.2 Results 
Hormonal evaluation 
-Effects of Estradiol Benzoate (EB 3-10 µg/rat), of DHEA (0,5-5 mg/kg) and co-administration of 
DHEA (0,5-5 mg/kg) plus EB (3 µg/rat) on Allopregnanolone (Allo) concentration in selective brain 
areas and in adrenal gland of ovariectomized rats.   
In all brain areas analyzed, with the only exception of the frontal lobe, the administration of EB at 
10 µg/rat in ovariectomized rats increased Allo content in comparison with EB 3 µg/rat. The 
administration of DHEA at the lower dose (0,5 mg/kg) did not evidence any significant difference 
in comparison with EB 3 µg/rat in all brain areas. On the contrary, DHEA 5 mg/kg increased Allo 
levels in comparison with EB at 3 µg/rat in all CNS areas evaluated. The co-administration of 
DHEA 0,5 mg with EB did not affect Allo level in all brain areas, in comparison with EB alone and 
with DHEA at 0,5 mg/kg. On the contrary, the co-administration of EB with the highest dose of 
DHEA (5 mg/kg) increased Allo levels respect to EB 3 alone in all brain areas and also in 
comparison with DHEA alone, at the dose of 5 mg/kg, in the parietal cortex, in the hypothalamus 
and in the anterior pituitary. In the adrenal gland, only the co-administration of DHEA (0,5 mg/kg 
and 5 mg/kg) with EB 3 increased Allo content in comparison with EB 3 alone, whereas all other 
hormonal treatments did not affect its intra-glandular concentration. 
 
-Effects of Estradiol Benzoate (EB 3-10 µg/rat), of DHEA (0,5-5 mg/kg) and co-administration of 
DHEA (0,5-5 mg/kg) plus EB (3µg/rat) on Beta-endorphin (β-end) concentration in selective brain 
areas.   
In all brain areas analyzed, with the only exception of the frontal lobe, EB, when administered at the 
dose of 10 µg/rat increased β-end content respect to EB at 3 µg/rat. The administration of DHEA 
alone at the lower dose (0,5 mg/kg) did not evidence any significant differences in comparison with 
EB 3 µg/rat in all brain areas. DHEA treatment at the dose of 5 mg/kg increased β-end levels in 
comparison with DHEA 0,5 mg/kg and in comparison with EB 3 µg/rat in hippocampus, in the 
hypothalamus and in the neurointermediate lobe. The co-administration of DHEA 0,5 mg with EB 
did not modify β-end level in all brain areas analyzed. On the contrary, the co-administration of EB 
with the highest dose of DHEA (5 mg/kg) increased β-end respect to EB 3 µg/rat alone in all brain 
areas and also in comparison with DHEA alone at the dose of 5 mg/kg in the hypothalamus. 
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-Effects of Estradiol Benzoate (EB 3-10 µg/rat), of DHEA (0,5- 5 mg/kg) and co-administration of 
DHEA (0,5-5 mg/kg) plus EB (3µg/rat) on circulating hormonal levels.  
Female rats receiving EB 10 µg/rat, DHEA 5 mg/kg and the co-administration of DHEA + EB (5 
mg/kg + 3 µg/rat) showed an increased levels of circulating estradiol in comparison with EB 3 
µg/rat. Administration of DHEA at 0,5 mg/kg alone showed reduced levels of estradiol compared to 
EB 3, whereas no modifications on estrogen levels were found following the co-administration of 
EB + DHEA 0,5 in comparison with EB 3.  
Plasma level of DHEA was found increased following the administration of both doses of DHEA 
alone or in co- administration with EB, evidencing a dose-related increase, although the presence of 
EB did not modify plasma level of DHEA. 
Only animals receiving DHEA alone or in combination with EB showed increased level of 
testosterone in comparison with EB 3 or EB 10. In these animals, T level were not affected by the 
dose of EB, while the concentration of T were higher in rats treated with DHEA 5 in comparison 
with those receiving DHEA at the dose of 0,5 mg/kg. 
Progesterone and corticosterone circulating levels were not modified following the administration 
of any dose of EB, DHEA or their co-administration.    
Allo levels resulted significantly increased following treatments with EB 10 and with the co-
administration of DHEA 5 + EB 3 in comparison with EB 3 alone. DHEA therapy alone, at 0,5 
mg/kg and 5 mg/kg, did not affect the concentration of this steroid compared to EB 3.  
Beta-endorphin circulating levels were increased only following the administration of the EB 10, 
DHEA 5 mg and the combination of DHEA 5 + EB 3 in comparison with EB 3 alone. 
 
Behavioural tests 
1) Receptivity test 
The oral administration of DHEA alone at both dosages failed to induce receptive behaviour in 
female rats, even if they were treated with progesterone; therefore their LQ values were always 
undetectable over the 4 weeks (data not shown). Rats treated with EB dosed at 10 µg/rat exhibited 
high level of sexual receptivity (LQ= 68.6 after 1 week of treatment, 93.8 after 2 weeks, 97.5 after 3 
weeks and 90.0 after 4 weeks) (Fig.1). Rats treated with EB dosed at 3 µg/rat showed a lower level 
of sexual receptivity in comparison with EB 10 µg/rat treated rats, except for the first week test 
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(LQ= 71.4 after 1 week of treatment, 77.5 after 2 weeks, 73.8 after 3 weeks, 81.4 after 4 weeks) 
(Fig.1). Female rats treated with EB 3 µg/rat and DHEA 0.5 mg/kg displayed LQ values which 
were not statistically different from those of EB treated rats at the same dosage (3 µg/rat). The 
administration of DHEA dosed at 5 mg/kg in EB treated rats induced a significant increase in LQ 
value in comparison with EB alone treated rats, only after 1 week of treatment (p<0.05) (Fig.1). It 
must be underlined that LQ value was significantly higher than that of EB 10 treated rats (p<0.05) 
(Fig.1).  In the following tests performed after 2, 3 and 4 weeks the difference in LQ values 
between EB + DHEA and EB alone treated rats was not statistically different (Fig.1). As concerns 
proceptive behaviours detected during the test, female rats treated with EB and DHEA at both 
dosages exhibited a marked increase in comparison with EB (3 µg/rat) treated rats already after the 
first week of treatment (p<0.05) (Fig. 2). Starting from the second week the difference between 
EB+DHEA and EB alone treated rats was statistically significant only when the highest dose of 
DHEA was administered (p<0.05 after 2 weeks, p<0.001 after 3 and 4 weeks) (Fig.2). It must be 
underlined that the number of proceptive behaviours exhibited by DHEA 5 mg/kg  + EB 3 µg/rat 
was higher than that of EB 10 µg treated rats, at any tested time (Fig.2). No difference was detected 
in the number of rejective behaviours among the different experimental groups (data not shown).  
2) Partner preference test 
As expected, rats submitted to EB treatment at both dosages showed a marked preference to visit 
the male rat rather than the female (p<0.05) (Fig.3 panel A). Consequently the preference score of 
EB treated rats was 0.77  following the injection of 10 µg/rat and  0.70 following the injection of 
the lower dose (3 µg/rat) (Fig.3 panel B). Female rats treated with DHEA alone failed to show a 
preference for the sexual or the social stimulus (Fig.3 panel A): therefore the preference score of 
both treated groups was approximately 0.50 (Fig.3 panel B). Rats administered with DHEA at both 
dosages and EB (3 µg/rat) exhibited a significant preference for the male rat (Fig.3 panel A): the 
preference score was found to be 0.73 in both treated groups (Fig.3 panel B).    
3) Paced mating behaviour 
Paced mating test was performed only in 3 groups of rats treated as follows: 1) EB 10 µg/rat; 2) EB 
3 µg/rat; 3) EB 3 µg/rat + DHEA 5 mg/kg. 
  As shown in Fig.4, there was a significant main effect of type of sexual stimulation on contact-
return latencies  (mount<intromission<ejaculation). It must be stressed that the mount, intromission 
and ejaculation contact return latencies of EB 3 + DHEA 5 mg/kg  treated females were lower than 
that of EB (3 µg/rat) treated rats: the difference was found statistically significant as regards the 
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latency to return to male’s compartment after ejaculation (p<0.05) (Fig.4). For percentages of exits, 
there was a significant main effect of type of sexual stimulation but not a main effect of treatment 
(data not shown).    
7.3 Conclusions 
Sex steroids directly modify sexual function, evidenced as changes in sexual behaviour and in 
variations in the neurobiology of neuropetides and neurosteroids involved in sexual function.  
It’s well established by previous studies that ovariectomy reduces female brain content of allo and 
beta-endorphin in the hypothalamus and in sovra-hypothalamic areas and that two-weeks treatment 
with estrogens or DHEAS were able to increase the level of endogenous opioid and 
neurosteroidogenesis in a dose-related response. (83) 
The present study confirms that chronic treatment (six weeks) of ovariectomized rats with DHEA 
only at the dose of 5 mg/kg increases allopregnanolone and beta-endophin content in different brain 
areas and in plasma when compared with available reference values of ovariectomized rats (16). 
Similarly, circulating hormonal changes after treatment with both doses of DHEA results in 
physiological increase of plasma estradiol, within the available range values of fertile animals (16) 
and no significant change of adrenal function (corticosterone level) were observed after treatment. 
These results, together with the available previous data, confirm that these animals received doses 
of DHEA inducing a biological response in a physiological range.  
A single injection of EB at the higher dose (10 µg/rat) increased allopregnanolone and beta-
endorphin brain and circulating content, supporting the concept that both systems are positively and 
directly influenced by estrogens in a dose-related way. Interestingly, co-administration of EB and 
DHEA showed a synergic effect on brain neurosteroidogenesis and opioid content compared to 
single treatments, although EB and DHEA therapies had a different time-schedule. In particular, 
this effect was shown over different brain areas and it was evidenced comparing animals receiving 
EB (3 µg/rat) and DHEA (5 mg/kg) as single therapy with rats receiving the combination of both. 
Opioid receptor agonists infused into the lateral ventricles can inhibit (through mu receptors) or 
facilitate (through delta receptors) the lordosis behavior of ovariectomized (OVX) rats treated with 
estrogen and a low dose of progesterone. 
The sexual effects of beta-endorphin are reputed to occur mainly through their action on the pre-
optic area and the amigdala (101). Beta-endorphin infused into the medial pre-optic area inhibits   
mounting and intromission; infusion of this peptide into the medial amygdala inhibits the initial 
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appetitive phase (101-102). However, according to Argiolas (103) the inhibitory effect is dose 
dependent, with low doses of opiate having facilitatory effects and with high doses inhibitory ones 
and beta-endorphin may facilitate appetitive behaviour by acting on the ventral tegmental area to 
activate the mesolimbic dopaminergic system. 
On the contrary, brain infusion of Allo positively affects all aspects of socio-sexual activities, 
enhancing exploratory, anti-anxiety and social function, (85). In particular, Allo plays a critical role 
in promoting sexual function in female rats: midbrain levels of this neurosteroid directly correlate 
with the onset and duration of lordosis and mating behaviour (85). 
Although DHEA is not a main hormone in rats, it can be metabolized to estrogens and delta-4 
androgens in different rat peripheral tissues and in brain by the widespread distribution of 17beta-
HSD (104). However, the increase of circulation testosterone levels in rats receiving only DHEA 
did not induce any significant changes in sexual behavior. On the contrary, when animals received 
the conditioning treatment with EB, DHEA therapy amplified measures of sexual motivation.  In 
addition, DHEA influence on brain function is multifaceted and it is not only a brain pre-hormone 
for estrogens and testosterone synthesis: DHEA acts as a modulator of neurotransmitter receptors, 
such as gamma-aminobutyric-acid-type A, N-methyl-D-aspartate, sigma subtype 1 (σ1) receptor, 
and glycine receptor, in addition to opioids and allopregnanolone. (104) 
These brain specific effects of DHEA seems to be important for sexual function, since DHEA, but 
not its conversion to testosterone, alleviates the suppressive effects of social stress on copulatory 
behavior via σ1 receptors in male rats. (102) 
It can be assumed that chronic treatment with DHEA might enhance or balance the biological 
response of certain brain circuits to the acute administration of EB, with neurochemical, hormonal 
and behavioral consequences, especially for sexual function.   
Indeed, the present study on female sexual behaviour shows that the administration of DHEA in EB 
treated rats is able to enhance receptivity only after 1 week of treatment, while significantly 
increasing proceptive behaviours at any tested time.  Proceptivity values were always found higher 
than that detected in EB 10 µg treated rats. There is a general agreement that an increased frequency 
of proceptive behaviours could be indicative of an increased sexual motivation (105). 
In the partner preference test, the preference score of EB +DHEA treated rats (0.73) was slightly 
higher than that of EB 3µ treated rats (0.70) but lower than that of EB 10 µ treated rats (0.77). The 
differences in the time and in the number of visits among EB + DHEA treated rats and EB 3µg 
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treated ones were not statistically significant. This finding is apparently in contrast with the 
observed increase in proceptivity during the receptivity test. It was suggested that the preference for 
a sexually appropriate partner is an index of the female sexual motivation and it is dependent on 
distal cues of the partner (auditory, visual and olfactory) rather than on coital stimulation (105). 
However it must be pointed out that the sexual motivation was tested during the receptivity test in a 
contact condition, while during the partner preference it was tested in a no-contact condition. 
Therefore DHEA seems to affect sexual motivation more markedly when physical contact was 
unrestricted (contact condition) than when physical contact was restricted (no-contact condition).   
Also the results obtained in the paced mating test might suggest an increased motivation as 
indicated by reduced contact return latencies corresponding to a lower time spent by the female in 
her own compartment. While the contact return latency is thought to be a measure of sexual 
motivation, the percentage of exits is thought to be a measure of sensory discrimination. Therefore 
the lack of effect of DHEA on the percentage of exits suggests a direct central effect on motivation 
rather than an influence on the peripheral sensitivity. 
Taken together these results support the positive effect of DHEA treatment on central aspects of 
sexual function with particular regard to motivation, at least in a model of female rats.  
 
 
 
 
 
 
 
 
 
 
 
 
	   34	  
Fig.1  
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Effect of estradiol benzoate (EB), dosed at 3 and 10 µg/rat, and DHEA dosed at 0.5 and 5 mg/kg 
coadministered with EB (3µg/rat) on lordosis quotient (LQ) in ovariectomized rats after 1, 2, 3 and 
4 weeks of treatment. Progesterone was injected 4 h before the test in all experimental rats. Values 
are mean ± SEM, n = 8. One-way ANOVA followed by Newman-Keuls post-test: #P<0.05 vs EB 
10; *P<0.05 vs EB 3 treated groups. 
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Fig. 2 
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Proceptive behaviors exhibited by ovariectomized rats treated with estradiol benzoate (EB) dosed at 
3 and 10 µg/rat, and DHEA at the doses of 0.5 and 5 mg/kg coadministered with EB 3µg/rat, during 
the receptivity test performed after 1, 2, 3 and 4 weeks of treatment. Progesterone was injected 4 h 
before the test in all experimental rats. Values are mean ± SEM, n = 8. One way ANOVA followed 
by Newman-Keuls post-test: #P<0.05 vs EB 10, *P<0.05, ***P<0.001 vs EB 3 treated groups. 
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Number of visits to the male and the female stimulus animals (panel A) and preference score (panel 
B) exhibited by ovariectomized rats treated with estradiol benzoate (EB) dosed at 3 and 10 µg/rat 
and DHEA, coadministered with EB 3 µg/rat or alone, at the doses of 0.5 and 5 mg/kg, during the 
partner preference test performed after 5 weeks of treatment. Progesterone was injected 4 h before 
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the test in all experimental rats. Values are mean ± SEM, n = 8. One way ANOVA followed by 
Newman-Keuls post-test: *P<0.05 vs visits to the male. 
 
Fig. 4 
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Contact return latencies exhibited by ovariectomized rats treated with estradiol benzoate (EB) dosed 
at 3 and 10 µg/rat and DHEA 5 mg/kg coadministered with EB 3 µg/rat, during the paced mating  
test performed after 6 weeks of treatment. Progesterone was injected 4 h before the test in all 
experimental rats. Values are mean ± SEM, n = 8. One way ANOVA followed by Newman-Keuls 
post-test: #P<0.05 vs EB 10, *P<0.05 vs EB 3 treated rats. 
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7. DHEA EFFECTS ON CLINICAL MEASURES OF DEPRESSION, ANXIETY AND 
QUALITY OF LIFE IN WOMEN 
Unlike DHEA(S) concentrations that decline under conditions of chronic stress and medical illness, 
cortisol concentrations generally either rise or do not change, and subsequently result in a decrease 
in DHEA(S)-to-cortisol ratios (106-109) As described previously, DHEA(S) and cortisol have 
different and often antagonistic effects on each other. The significance of considering DHEA(S)-to-
cortisol ratios is exemplified by the concept of “anabolic balance,” which considers the ratio of 
anabolic to catabolic hormones and may indicate susceptibility to diseases of stress and aging (110). 
Hormones co-regulate each other, and together, co-elevations or imbalances determine net effects 
on tissues. Therefore, it may be important to consider the ratio of both steroids in addition to their 
absolute concentrations. For example, greater cognitive deterioration was observed in elderly men 
and women who showed larger decreases in plasma DHEAS-to-cortisol ratios over a two-year 
period, although changes in DHEAS concentrations alone were not significantly correlated with 
cognitive change (111). Frail, institutionalized elderly people did not differ from independent 
community-dwelling controls in serum concentrations of cortisol or DHEAS, but did have 
significantly lower DHEAS-to-cortisol ratios (112). 
Both DHEAS and cortisol are considered in the calculation of allostatic load, which is a measure of 
the cumulative physiological burden to the body of accommodating multiple stressors over time 
(113). Allostatic load scores are based on ten biological parameters, including DHEAS, cortisol, 
epinephrine, norepinephrine, high density lipoproteins (HDL), total cholesterol, waist-to-hip ratio, 
glycosylated hemoglobin (HbA1C), systolic blood pressure, and diastolic blood pressure. High 
cortisol concentrations and low DHEAS concentrations contribute to increases in allostatic load 
score. The hormonal profile contained within the measure of allostatic load by itself serves as a 
stronger predictor of cardiovascular disease than the traditional cardiovascular disease risk factors 
alone (114) 
According to current theories of the biology of depression, DHEA(S)’ ability to modulate many 
neurobiological actions, including glutamate and σ1 receptors, catecholamines, neurogenesis, 
neuroprotection, anti-glucocorticoid, anti-inflammatory and anti-oxidant properties could all 
underlie relationships between endogenous and/or exogenously-supplemented DHEA(S) 
concentrations and depression. An assessment of depression ratings in relation to plasma 
concentrations of several steroid hormones (estradiol, testosterone, estrone, androstenedione, 
cortisol, DHEA, and DHEAS) in 699 non-estrogen using, community dwelling, postmenopausal 
women (aged 50–90 years) (115) found that only DHEAS concentrations were negatively correlated 
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with ratings of depressed mood. Specifically, higher DHEAS concentrations were associated with 
less depression, and this association was independent of age, physical activity and weight change. 
Furthermore, women with categorical diagnoses of depression had significantly lower plasma 
DHEAS concentrations compared to age-matched non-depressed women (115) Similarly, in a large-
scale study of 2,855 well-functioning elderly men and women, serum DHEAS concentrations were 
inversely correlated with depressive symptoms. In a study looking at both DHEA and DHEAS in 
plasma, depressed patients had low DHEAS concentrations but normal DHEA concentrations. 
Women whose first onset of major or minor depression occurred during peri-menopause showed 
low morning plasma DHEA and DHEAS concentrations. Lower plasma DHEA concentrations 
during pregnancy and during the postpartum period were associated with higher postpartum ratings 
of depression. Dysthymic patients have also been shown to have low serum DHEAS concentrations. 
The remaining literature examining plasma and serum DHEA(S) concentrations in depression is 
inconsistent, with the decreased DHEA(S) findings described above, and with reports of either 
increased  or unaltered  DHEA(S) concentrations in depressed patients. A study examining diurnal 
salivary concentrations of DHEAS and cortisol in a small group of medicated but still depressed 
patients with unipolar depression, found that depressed patients had elevated DHEAS 
concentrations compared to controls.  
Several groups have found that DHEA-to-cortisol ratios in serum and saliva, rather than 
concentrations of either hormone alone, more accurately discriminate depressed from non-
depressed individuals (116) with lower morning ratios seen in depression (116. The molar DHEA-
to-cortisol ratio was significantly lower in the un-medicated depressed patients than in controls, and 
the evening salivary DHEA-to-cortisol ratio ratios were inversely correlated with the lengths of 
current depressive episodes. Morning salivary DHEA hyposecretion as well as evening cortisol 
hypersecretion were significantly and independently associated with major depression in 8- to 16-
year-olds. Patients who remained depressed several months after the initial assessment had lower 
salivary DHEA-to-cortisol ratios at baseline. Elevated DHEA(S) concentrations, relative to cortisol, 
may blunt the negative effects of high cortisol concentrations on depression.  
The relationship between DHEA(S) concentrations and depression is complex. There is no 
parsimonious way of reconciling the diverse findings, but age of the subjects studied, demographic 
variables, comorbid psychiatric and medical diagnoses, acute vs. chronic stress, medication status 
and timing of the sample collection, are likely relevant. Gender may also have a significant impact. 
In a prospective study of a nationally representative sample, men with initially lower serum 
concentrations of DHEAS had greater increases in depression ratings over a three-year period; this 
relationship in men was not observed in women. Among African-American women (but not men), 
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lower serum DHEAS concentrations were associated with higher depression ratings. In another 
study, men with recurrent unipolar depression had low 24-hour urinary DHEA concentrations but 
normal cortisol concentrations, while women had normal DHEA concentrations but elevated 
cortisol concentrations. However, in both cases, the DHEA-to-cortisol ratios appeared to be low, 
suggesting that the anabolic balance may be a helpful way of identifying common states of general 
hormonal imbalances in certain clinical conditions. 
 
7.1. Anxiety Spectrum Disorders  
As reviewed above, DHEA(S) has prominent effects on GABAA receptor activity; these effects 
could be involved in the relationship between DHEA(S) and anxiety disorders. Increased plasma 
concentrations of DHEA were observed in male patients with panic disorder but not in females , 
and increased serum DHEAS-to-cortisol ratios were reported in a sample of patients of both genders 
who had panic disorder. Social anxiety disorder (also called social phobia), was not found to be 
associated with alterations in plasma DHEA(S) concentrations  
The anxiety disorder that has received the greatest attention with regard to plasma, serum, and 
salivary DHEA(S) concentrations is post-traumatic stress disorder (PTSD) Studies have uniformly 
identified elevated DHEA and/or DHEAS concentrations in PTSD, as well as increases in the 
DHEA(S)-to-cortisol ratioUntreated men with combat-related PTSD were found to have increased 
plasma DHEA and DHEAS concentrations Another study found that PTSD patients who attempted 
suicide had increased plasma DHEA concentrations. Female victims of intimate partner violence 
with PTSD had increased evening salivary cortisol concentrations and increased morning and 
evening salivary DHEA concentrations compared to non-abused women . However, salivary DHEA 
concentrations were not significantly correlated with PTSD ratings. In a study of recently resettled 
refugees in Sweden, those with PTSD (but without depression) had elevated plasma DHEAS 
concentrations compared to refugees with neither PTSD nor depression. Over nine months of 
follow-up in these refugees, increases in PTSD symptoms were associated with increases in plasma 
DHEAS concentrations. 
Despite the uniformity of studies showing elevations in DHEA or DHEAS in PTSD, researchers 
have suggested that the increase in DHEA(S) is salutary rather than pathophysiologic. Pre-
menopausal women with chronic PTSD had increased plasma DHEA responses to ACTH 
stimulation compared to healthy, non-traumatized participants. In the women with PTSD, the peak 
change in plasma DHEA (in response to ACTH) was negatively correlated with PTSD symptoms, 
suggesting that increased capacity of adrenal DHEA release may mitigate the severity of PTSD 
symptoms. Consistent with that interpretation, another group found that, although plasma DHEA 
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and DHEAS concentrations were elevated in male veteran PTSD patients, concentrations of both 
hormones were directly correlated with symptom improvement and better coping. In another study, 
PTSD patients who responded to psychotherapy with a decrease in PTSD symptoms had an increase 
in DHEA concentrations in plasma, while patients who did not respond to psychotherapy had 
decreases in DHEA concentrations (after controlling for depressive symptoms). 
Increased DHEAS concentrations under conditions of stress may indicate a salutary process. 
Although not in PTSD patients per se, a study of 19 men undergoing stressful military training 
including captivity exercises showed significant increases in both cortisol and DHEAS in saliva 
during the acute stress of training. Performance during a low intensity captivity challenge (but not 
during a high intensity one) was positively correlated with salivary DHEAS concentrations. In 
another study of 25 elite special operations soldiers exposed to prolonged and extreme training 
stress, soldiers experiencing fewer symptoms of dissociation and showing superior military 
performance had significantly higher ratios of plasma DHEAS-to-salivary cortisol. In light of such 
data, DHEA(S) has been proposed to play a role in resilience and in successful adaptation to stress 
(117-119). 
 
Many, but not all, studies have reported lowered serum concentrations of DHEA(S) in patients with 
poor life satisfaction, psychosocial stress and functional limitations. Low plasma and serum 
concentrations of DHEAS have been associated with higher ratings of perceived stress, trait anxiety, 
as well as Type A behavior, cynicism, and hostility. Higher plasma and serum DHEAS 
concentrations have been associated with higher levels of functioning, higher likelihood of living 
independently and a lower likelihood of organic brain syndrome in men. Higher plasma and serum 
concentrations of DHEAS have also been associated with greater amount, frequency, and 
enjoyment of leisure activities, sexual gratification and frequency of masturbation (in women), 
healthier psychological profiles (90), more expansive personality ratings, and greater sensation-
seeking and monotony-avoidance attributes. Most of these studies examined concentrations of 
DHEAS rather than DHEA, and many assessed female rather than male populations, so the 
generalizability of these findings is uncertain. In some studies, the relationships were gender-
specific . 
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7.2 Effect of DHEA administration on depressive symptoms 
Although clinical trials of DHEA treatment for depression are few in number, they consistently 
suggest beneficial effects. In an initial small-scale, open-label pilot study, DHEA treatment resulted 
in significant antidepressant effects in un-medicated middle-aged to elderly patients with major 
depression (121). The doses of DHEA were individually adjusted between 30 and 90 mg per day for 
four weeks to achieve circulating DHEA and DHEAS concentrations in the mid-to-high normal 
physiologic range for healthy young adults. Subjects demonstrated highly significant improvements 
in Hamilton Depression Ratings and Symptom Checklist-90 ratings. Mood improvements were 
significantly related to increases in the circulating concentrations of DHEA and DHEAS and to 
their ratios with cortisol; changes in cortisol concentrations alone were not correlated with 
behavioral changes (120) This small open-label study was followed by a double-blind, placebo-
controlled trial in which 22 depressed patients received either DHEA (60 to 90 mg per day) or a 
placebo for 6 weeks (121). Some patients were medication-free at the time of entering the study; 
others remained depressed despite being on pre-stabilized (for a minimum of 6 weeks) 
antidepressant medication. In the former group, DHEA or the placebo was used alone; in the latter 
group, DHEA or the placebo was added to the stabilized antidepressant regimen. DHEA, compared 
to the placebo, was associated with significant antidepressant responses. Five of 11 DHEA-treated 
patients showed greater than 50% improvement in depression ratings and had endpoint Hamilton 
Depression Rating Scale ratings of less than 10, suggesting that they had responded to treatment. 
None of the 11 placebo-treated patients achieved these milestones (121). These results raised the 
possibility that DHEA, used alone or as an antidepressant adjunct in refractory patients, has 
significant antidepressant effects in some patients. Subsequently, another research group conducted 
a 12-week, double-blind, placebo-controlled study in un-medicated patients with mid-life dysthymia 
(one subject also had concurrent major depression) (39).  
Second, the psychological symptoms of depression improved in both studies to a greater extent than 
the neurovegetative symptoms (e.g., sleep and appetite disturbances). Third, baseline serum DHEA 
concentrations did not predict antidepressant response, suggesting that DHEA supplementation was 
not simply correcting a DHEA deficiency in these patients (in which case, it would be expected to 
work only in those with low DHEA at baseline). Finally, responders to DHEA in both studies 
achieved higher serum DHEA concentrations following treatment than did non-responders, and 
antidepressant effects were directly correlated with changes in serum DHEA concentrations. This 
concordance across two separate studies in different populations strengthens the argument that the 
DHEA treatment itself is related to the antidepressant responses. 
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Thus, to date, every controlled trial of DHEA in depression has reported significant antidepressant 
effects. Although these data are encouraging, more large-scale studies will be required to establish 
the place, if any, of DHEA in the management of patients with depression. For example, there have 
been no head-to-head trials comparing DHEA to standard antidepressants, although in at least one 
trial, antidepressant non-responders did respond to DHEA augmentation. The risks and benefits of 
long-term DHEA administration also remain to be further clarified. 
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8. EFFECT OF DHEA ON SEXUAL FUNCTION IN WOMEN 
Menopause is an individual experience that derives from a complex interplay of biological, 
psychological and relationship factors that collectively affect the physical, mental and sexual well-
being of many women. Natural menopause is associated with a high rate of sexual symptoms. The 
reported prevalence of these varies and seems to depend on several factors, including the study 
sample (e.g. the women’s socio-cultural background), the study design and the specific symptoms 
selected . Ageing and menopausal transition may in themselves impair the integrity of multiple 
biological systems involved in the normal sexual response. In addition, though, intrapersonal and 
interpersonal issues can affect feminine identity and sexual relationships. Inadequate hormone-
dependent vulvo-vaginal receptivity (genital arousal, lubrication) is likely to cause sexual pain 
disorders, with profound consequences for sexual desire, mental arousal, orgasmic capacity and 
sexual satisfaction. Across the menopausal transition, the estradiol (E2) level is one of the best 
predictors of sexual function. Nonetheless, several domains of sexual response, such as sexual 
desire, sexual arousal and well-being, are commonly attributed to circulating androgens.  
Taking into consideration that endogenous hormone levels may be poor indicators of their effects in 
target tissues, various studies have explored the relationships between androgens and clinical 
characteristics including sexual function, well-being, cardiovascular disease (CVD) risk, insulin 
resistance, and cognition. Relationships between androgens and sexual function were investigated 
in a cross-sectional study of 1423 non-health care-seeking women, aged 18 to 75 yr, randomly 
recruited from the community via the electoral roll, of whom 1021 completed a validated sexual 
function questionnaire (122). Androstenedione and total and free T were not related to sexual 
function scores. However, women aged 45 yr or more with low sexual responsiveness had a greater 
likelihood of having a serum DHEAS value below the 10th centile for their age (odds ratio (OR), 
3.9;95%confidence interval (CI), 1.54–9.81; P   0.004). For women aged 18 to 44 yr, having low 
sexual desire, sexual arousal, or sexual responsiveness was also associated with having a DHEAS 
value below the 10th centile for their age  (122). Because the normal range for serum DHEAS 
among young women is relatively large and a significant proportion of women with low DHEAS do 
not have low sexual function, a cutoff level below which women can be said to be more likely to 
have low sexual function cannot be identified. A smaller study of women attending a sexual 
medical center diagnosed with hypoactive sexual desire disorder, compared with controls, also 
reported an association between low DHEA and DHEAS and impaired sexual function (123).   
Because it has been proposed that DHEA and DHEAS may exert neuroprotective effects, 
associations between endogenous DHEAS levels and cognitive performance in women aged 21 to 
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77 yr have been investigated. Women with higher levels of DHEA Sexhibited better performance 
on testing of executive function, with circulating DHEAS levels being significantly positively 
associated with higher scores for tests of simple concentration and working memory in women with 
at least 12 yr of education (124). 
 
Exogenous DHEA Treatment 
It has been proposed that treatment of postmenopausal women with DHEA will result in androgenic 
effects and hence improve libido and well-being via its conversion to T and estrogenic effects 
resulting in improvements in menopausal vasomotor symptoms. DHEA has been administered 
orally and parenterally, either by the transdermal or vaginal route. When administered to 
postmenopausal women, DHEA is mainly transformed to androgens rather than estrogens. Using 
liquid chromatography combined with tandem mass spectrometry, an oral dose of DHEA 50 
mgdaily for 12 months (125) results in significant increases in estrone and estradiol, in the order of 
34 and 57%, respectively, and a 200% increase in 5-diol. With this oral dose, total T levels increase 
by about 100%, serum DHT is relatively unchanged, and serum 3 -diol,3G, 3 -diol,17G, and ADT-
G each increase 4- to 5-fold (125). These changes contrast with those reported in a 12-month study 
of transdermal DHEA using the same methodology for steroid measurements by the same 
laboratory (126). Irrespective of dose, with transdermal DHEA similar proportional increases in 
estrone, estradiol, and 5-diol were observed to those seen with oral DHEA, whereas the sum of 
ADT-G 3 -diol,3G and 3 -diol,17G increased by only 71% (126). Giagulli et al. and others have 
shown that hepatic 5 -reductase is a major determinant of the conversion of precursors to plasma 
ADT-G. This would be consistent with the mode of administration of DHEA influencing its 
metabolism, such that the higher ADT-G levels seen with oral DHEA reflects first past hepatic 
metabolism and not peripheral androgen formation. 
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Studies of DHEA for Sexual Function 
Although the prevalence, incidence, and antecedents of female sexual dysfunction remain under-
researched, the most commonly reported sexual problems in women relate to sexual desire and 
interest, pleasure, and global satisfaction. To date, there are eight published randomized trials of 
oral DHEA treatment for low sexual function in healthy, postmenopausal women. These are 
summarized in Table below (125-134). Some of the studies demonstrated a positive effect of DHEA 
treatment on sexual function whereas others did not show any benefit. Of the three trials where a 
benefit was shown, two administered supraphysiological DHEA doses and were of short duration). 
The third study was of older aged women and employed a nonvalidated measure of sexual function 
that was understood by only 25% of the participants. The early studies in which DHEA was 
ineffective were also limited by small sample size, short treatment duration, use of nonvalidated 
instruments, or supraphysiological doses. More recent studies have employed validated measures of 
sexual function, have larger sample sizes, and are of longer duration. Two different studies with a 
52-wk treatment phase have shown no improvement in sexual function with DHEA 50 mg daily. 
One was in 115 older, postmenopausal women, and sexual function was assessed by the Female 
Sexual Function Index. In the other, which excluded women with dyspareunia, sexual function was 
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assessed by two methods: a validated questionnaire and a 28-d diary of satisfactory sexual events . 
In contrast, the use of vaginal DHEA has been evaluated over 12 wk in women primarily presenting 
with dyspareunia and subjective vaginal dryness and irritation. Vaginal atrophy was reversed with 
minimal changes in serum steroid hormone levels, which remained within the normal 
postmenopausal range. Beneficial effects on four aspects of sexual dysfunction, desire/interest, 
arousal, orgasm, and pain at sexual activity were reported for this study. These data suggest that 
local combined androgenic/estrogenic stimulation in the vagina may exert favorable effects on 
sexual function in women suffering from vaginal atrophy. Unfortunately, the number of women 
allocated to each treatment group in this study was small, and the study reports do not provide 
information regarding the number of women in each arm that completed the study. Hence, the 
findings need to be reproduced in a larger study of longer duration before DHEA can be considered 
a therapeutic option for the management of vaginal atrophy. Whether these effects hold for women 
without vaginal atrophy remains to be investigated. Overall, the evidence from published RCT does 
not support efficacy of systemic DHEA therapy for the treatment of female sexual dysfunction. 
However, vaginal application of DHEA may benefit postmenopausal women with vaginal atrophy 
experiencing dyspareunia. 
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9. EFFECT OF 1-YEAR, LOW-DOSE DHEA THERAPY ON CLIMACTERIC SYMPTOMS 
AND FEMALE SEXUALITY 
The effects of DHEA therapy on sexual function in postmenopausal women are controversial and 
there is still no conclusive evidence for its clinical use. On this basis, we aimed to evaluate the 
effects exerted by 1-year, low-dose oral DHEA therapy (10 mg/day) in symptomatic 
postmenopausal women on measures of sexual function and on hormonal changes in comparison 
with other three active treatments: daily oral continuous combined treatment with 1 mg micronized 
17 β -estradiol plus 5 mg dydrogesterone or oral tibolone (2.5 mg/day) or vitamin D/calcium 
carbonate. 
 
9.1 Methods 
Department of Obstetrics and Gynecology, University of Pisa and from the Francavilla Fontana 
Hospital ‘ D. Camberlingo ’ , Italy, were enrolled in the study. All subjects had natural menopause 
and were healthy. Exclusion criteria for patient enrolment were: previous or current endocrine 
disorders, such as thyroid or adrenal dysfunction or altered prolactin circulating levels; treatment of 
cardiovascular diseases, hypertension or psychiatric disorders; previous or current hormone 
treatments known to influence endocrine function; smoking; presence of any kind of pelvic and 
breast disease. Natural menopause was defined retrospectively after 12 consecutive months without 
natural menstrual periods, and age at menopause was the age at last menstruation. The same 
physician followed each patient monthly. The Local Committees approved the study protocol and a 
written informed consent was obtained from each subject before the beginning of the study. An 
accurate medical, urogynecological and obstetric history was taken, including use of medications 
and lifestyle risk factors, as part of the sexual history, with the aim of identifying any possible 
organic factor affecting desire, arousal, orgasm and sexual pain. Validated tools (self-administered 
questionnaires) were used to properly diagnose sexual symptoms and to gain information on any 
sexual relationship. The self-administered questionnaire used was the McCoy Female Sexuality 
Questionnaire (MFSQ) (135). The MFSQ is a 19-item questionnaire developed to assess sexual 
interest, satisfaction with frequency of sexual activity, vaginal lubrication, orgasm, and sexual 
partner. It was designed to measure aspects of female sexuality likely to be affected by changing 
sex hormone levels. We used an Italian validated version (136). Women who reported climacteric 
symptoms and who requested hormone therapy were randomized uniformly into three groups and 
received the following treatments: the first group (n 12) received DHEA 10 mg daily, the second 
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group (n  12) were given daily oral estradiol (1 mg) plus dihydrogesterone (5 mg) (HRT) (Femoston 
Conti ® , Solvay Pharma SpA), the third group (n   12) received one daily oral tibolone tablet (2.5 
mg) (Livial ® , Schering-Plough SpA). The fourth group (n 12) was formed from women who 
reported any climacteric symptoms and who refused hormone therapy; this group was treated with 
oral vitamin D (400 IU) plus calcium carbonate (1250 mg) (vitamin D group) to prevent 
osteoporosis. Randomization, in three hormone-treated groups, was made using a computer-
generated block, random-permutation procedure. Compliance was checked by pill counts at 
monthly intervals. The study protocol was prospective and the treatment lasted for 12 months for all 
study subjects.  
Main outcome measures 
Each subject underwent a clinical and hormonal evaluation at baseline and at 3, 6 and 12 months of 
treatment. After overnight fasting, blood samples were obtained from each participant at 08.00 
before the initiation of each hormone treatment in order to assess the levels of DHEA, DHEAS, Δ 
4-androstenedione, testosterone, free testosterone, progesterone, estradiol, follicle stimulating 
hormone (FSH), luteinizing hormone (LH), sex hormone binding globulin (SHBG), cortisol, 
allopregnanolone, and β -endorphin. We also evaluated baseline levels of thyroid function. All 
blood samples were immediately centrifuged and stored at −20 ° C until required for the assay. 
Each patient underwent an ultrasound pelvic evaluation to measure endometrial thickness and an 
ultrasound evaluation of bone density by Achille Insight (GE Healthcare) at baseline and after 12 
months of treatment. All the patients completed the McCoy Questionnarie at baseline and before the 
end of study (after 12 months of treatment). 
Assays 
All hormonal determinations were carried out during the same assay. Plasma DHEA, DHEAS, Δ 4-
androstenedione, testosterone, cortisol, progesterone, estradiol, and SHBG concentrations were 
determined using commercially availablradioimmunoassay kits (Radim, Pomezia, Rome, Italy). The 
intra-assay and interassay coefficients of variation (CV) and the sensitivities of the assay were: 7.8, 
8.3% and 0.02 ng/ml for DHEA; 6.8, 8.5% and 0.02 ng/ml for DHEAS; 4.2, 7.6% and 0.03 ng/ml 
for Δ 4-androstenedione; 3.8, 8.7% and 0.017 ng/ml for testosterone; 6.2, 9.7% and 0.18 pg/ml for 
free testosterone; 4.9, 7.9% and 0.9 µ l/l for cortisol; 6.6, 11.7% and 0.12 ng/ml for progesterone; 
4.6, 8.5% and 4.7 pg/ml for estradiol; 6.2, 6.2% and 0.18 mIU/ml for FSH; 7.8, 8.2% and 0.20 
mIU/ml for LH; 3.8, 4.4% and 0.26 nmol/l for SHBG; respectively. Allopregnanolone evaluation 
was performed after extraction and chromatography partition on Sep-Pak C18 cartridges using our 
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previously used and described radioimmunoassay method (24). The sensitivity of the assay, 
expressed as the minimal amount of allopregnanolone distinguishable from zero, with 95% 
probability, was 20 pg/tube and the intra-assay and interassay CVs were 7.2 and 9.1%, respectively. 
The β -endorphin concentrations were determined after extraction and chromatography partition on 
Sep-Pak C18 cartridges, using a previously described radioimmunoassay method 25. The sensitivity 
of the assay was 2.5 pg/ml and the intra-assay and interassay CVs were 6.0 and 9.0%, respectively.  
Statistical analysis 
Data are expressed as mean standard error of the mean. Statistical analysis was carried out using 
Graph Pad Prism 4.0. Repeated measures one-way ANOVA, followed by a post-hoc analysis with 
Bonferroni multiple comparisons test, was used to evaluate differences in hormonal status and 
McCoy scores between the four groups. The α value for Bonferroni ’ s test was set at 0.05. 
 
9.2 Results 
Patient characteristics All those patients who enrolled in the study completed the follow-up, without 
any adverse events. No significant differences were observed for chronological age, menopausal 
age and body mass index (BMI) between all four groups. The baseline endometrial thicknesses and 
bone densities ( T –score calcaneal level) were similar in all groups (Table 1). 
Endocrine evaluation 
Baseline status 
Before the start of treatment, there were no differences between the four groups regarding levels of 
LH (Figure 1), estradiol, DHEA, DHEAS, Δ 4-androstenedione, testosterone, free testosterone, 
progesterone, 17-hydroxyprogesterone, SHBG, allopregnanolone and β -endorphin. We observed a 
difference at baseline in FSH levels between the DHEA (90.8±9.1), HRT (69.5 ±    10.7) and 
vitamin D (69.7± 19.7) groups ( p   0.05) (Figure 1), and in basal cortisol levels in the tibolone 
group (182.4 ±    15.2) vs. the DHEA group (204.5  ±   12.8) ( p   0.01) and the vitamin D group 
(208.7  ±   15.8) ( p   0.05). 
Post-treatment evaluation 
In women treated with DHEA, we observed a progressive significant increase in serum levels of 
DHEA (from 1.9   ±  0.6 to 2.7  ±   0.6 ng/ml) and of DHEAS (from 0.5 ±    0.1 to 0.8) 0.2 µ g/ml) 
during the entire treatment period, and an increase in Δ 4-androstenedione (from 0.9     0.1 to 1.28     
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0.2 ng/ml) ( p   0.001) and testosterone (from 0.32   ±  0.12 to 0.54   ±  0.06 ng/ml) ( p   0.05) levels 
from the 6th month, reaching the higher concentration at the 12th month. In the group treated with 
HRT, we observed no change in serum levels of DHEA, DHEAS, free testosterone and Δ 4-
androstenedione during the entire treatment period and a progressive decline in testosterone levels 
(from 0.4     0.1 ng/ml from the 3rd month of therapy ( p   0.001). In the group treated with tibolone, 
we observed no differences in androgen serum levels during the 12-month evaluation. 
Estradiol levels showed a significant increase in all hormone-treated groups. In women treated with 
DHEA, we observed a progressive increase from 20.10 ±  3.2 to 27.5  ±   2.8 pg/ml; in the HRT 
group, we observed an increase from 18.1   ±  2.0 to 59.0± 9.0 pg/ml; in the tibolone group, there 
was an increase from 18.1    ± 2.1 to 23.8  ±   2.3 pg/ml (p   0.001) (Figure 2). 
Progesterone levels showed a constant increase in the DHEA group (from 0.41     0.11 to 0.48     
0.11 ng/ml) and the HRT group (from 0.42  ± 0.07 to 0.51  ±   0.07 ng/ml) ( p   0.001). In women 
treated with DHEA, we observed an increase in progesterone levels and in 17-hydroxyprogesterone 
levels from the 6th month compared to baseline ( p   0.001). In the group treated with HRT, as we 
expected, we observed a significant increase in progesterone and 17-hydroxyprogesterone levels 
from the 3rd month of treatment ( p   0.05). In the tibolone group, we observed no change in 
progesterone and 17-hydroxyprogesterone levels during the entire treatment period. 
Allopregnanolone levels showed a constant increase in all hormone-treated groups. In the DHEA 
group, we observed a progressive increase from the 6th month (from 198.2 ±18.0 to 223±17.1 
pg/ml), and also in the tibolone group (from 197.3 ± 12.9 to 227.9  ± 18.8 pg/ml), and in the HRT 
group just from the 3rd month (from 210.1 ±  23.1 to 270.9± 35.5 pg/ml) ( p   0.001). 
Cortisol levels showed a significant reduction in all hormone-treated groups at the end of treatment 
( p   0.001). We observed a continuous increase in β -endorphin levels in all hormone-treated groups 
compared to the group given vitamin D and to baseline from the 3rd month. In the DHEA group, 
the β -endorphin level increased from 17.9 ±  3.0 to 35.3 ± 3.4 pg/ml; for the HRT group, it 
increased from 19.5  ±   2.3 to 41.2  ± 4.8 pg/ml; and for tibolone group, it increased from 17.2     
4.1 to 23.9  ±   4.6 pg/ml ( p   0.001). 
SHBG levels increased slowly and progressively in the DHEA group from the 6th month and in the 
HRT group from the 3rd month of treatment (p   0.05). In women treated with tibolone, we 
observed, as expected, a decrease in SHBG, more significant after 12 months of therapy (p   0.001). 
No significant differences in SHBG levels resulted between the groups throughout the follow-up 
period (Table 2). 
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Climacteric symptoms 
The severity of climacteric symptoms was analyzed using the Greene Climacteric Scale 26 at 
baseline and after the end of the active treatments. In particular, women receiving hormone 
treatments (DHEA, HRT or tibolone) had the same degree of climacteric syndrome at baseline, 
which was higher than in women receiving only vitamin D (15.1 ± 8.5). After 12 months, symptoms 
were improved in women treated with all hormone preparations, whereas no changes occurred in 
the group of women receiving vitamin D. 
McCoy Female Sexuality Questionnaire 
The four groups did not differ significantly with regard to baseline sexual function using the total 
score of the McCoy  
Female Sexuality Questionnaire. 
Before any treatments, in regard to the relationship total score, we observed a good baseline value 
in all the groups (Figure 1). As regard frequency of sexual intercourse in the previous 4 weeks (a 
single question in the McCoy test), we observed no differences between all groups at baseline. 
At the end of the study, we observed a significant increase from baseline in the McCoy 
Questionnaire total score in women treated with DHEA and with HRT. Women receiving tibolone 
also increased their mean score, although this value, after 1 year of therapy, did not result in 
statistical significance in comparison with baseline. No differences were evaluated between the 
DHEA and HRT groups at the end of the entire follow-up (48.6 ±4.6 and 47.6  ±   3.66, 
respectively). Furthermore, we observed a significant increase in sexuality total score between the 
DHEA and vitamin D groups (48.6   ±  4.6 and 34.9     ±4.82, respectively, p   0.001), and the HRT 
and vitamin D groups (47.6   ±  3.66 and 34.9 ±    4.82, respectively, p   0.01) (Figure 1). 
The relationship total score did not change from baseline to 1-year of treatment in any groups 
analyzed. The frequency of sexual intercourse in the last 4 weeks increased in women treated with 
DHEA, HRT and tibolone after 1-year therapy in comparison with the baseline score ( p   0.01; p   
0.05 and p   0.01, respectively). In addition, the extent of this modifi cation was the same for the 
DHEA, HRT and tibolone groups and no differences between these groups was observed at the end 
of treatment. The frequency of sexual intercourse did not change in women treated with vitamin D 
after 1 year and their scoring was significantly lower in comparison with those of women receiving 
hormone treatments ( p   0.05) (Figure 1). 
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9.3 Discussion 
The present study is evidence that symptomatic, early postmenopausal women receiving 1-year oral 
DHEA therapy at a daily dose of 10 mg improved their climacteric symptoms. The magnitude of 
this effect seems to be similar to the effect in women receiving 1-year therapy with tibolone or HRT. 
In addition, all hormone treatments used (DHEA, HRT and tibolone) improved the quality of sexual 
life in postmenopausal women, supporting the hypothesis that hormonal changes, during 
reproductive aging, negatively affect sexual function. 
This finding has been achieved in healthy women that did not have criteria for the diagnosis of 
sexual dysfunction, but who opted for hormone treatment to reduce their climacteric symptoms. 
Several trials have reported significant hormonal changes after DHEA administration in 
postmenopausal women. However, short follow-up and supraphysiological doses of DHEA (50 
mg/day or higher) hampered these studies. Administration of a lower dose (25 mg/day) of DHEA 
produces positive effects on the hormonal milieu and on quality of life in early and late 
postmenopausal women, restoring estrogenic, progestogenic and androgenic tone in the range of 
fertile women (137). 
In the present study, 1-year DHEA supplementation with 10 mg/day modified the endocrine milieu 
in postmenopausal women; this therapy enhanced plasma levels of estradiol and progesterone, it 
modified adrenal synthesis of cortisol (reduction) and allopregnanolone (increase) and it increased 
plasma concentration of β-endorphin, confirming our previous study and supporting also a direct 
action of DHEA on adrenal function. 
The different impact of DHEA, in comparison with tibolone and HRT, on the androgenic 
circulating profile is also confirmed in the present study in which DHEA increased plasma Δ 5 and 
Δ 4 androgens levels, whereas estrogen – progestin therapy or tibolone did not induce any changes. 
The beneficial effects of DHEA on sexual function might be, at least in part, the direct consequence 
of this concomitant increase of estrogens, androgens and progesterone in symptomatic 
postmenopausal women. Indeed, sex steroids (estrogens, androgens and progesterone) positively 
affect critical aspects of sexual function in the central nervous system and, peripherally, in the 
genital tract. In addition, DHEA is a neurosteroid that acts directly as a modulator of 
neurotransmitter receptors, such as γ -aminobutyric acid type A, N -methyl- D -aspartate, and 
sigma-1 receptors. 
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Interestingly, although the effect on sexual function is similar for DHEA and HRT, using the 
McCoy Questionnaire, estrogen – progestin treatment induced higher (almost double) values of 
circulating estradiol than DHEA, supporting the hypothesis that estrogens are not the only 
mediators of sexual function in women. On the contrary, tibolone might increase sexual function 
through its unique receptor profile, as previously evidenced. To our knowledge, no previous studies 
have evaluated the effects of oral, low-dose DHEA replacement therapy on sexual function, and, in 
particular, have analyzed the frequency of sexual function. Only one study by Labrie and colleagues 
has reported that vaginal daily DHEA treatment, using the dose of 6.5 mg enhances arousal, desire 
and lubrication in healthy postmenopausal women (evaluated using the Abbreviated Sexual 
Function (ASFQ) questionnaires). In this regard, our findings are promising, although they need 
further exploration with a larger and more representative sample size. 
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Comparison of McCoy score (sexuality total score, relationship total score, sexual intercourse total score) between 
groups before the start of the treatment (T0) and at the end (T12). Climacteric symptoms were evaluated by the Greene 
Scale. Vit. D, vitamin D; DHEA, dehydroepiandrosterone; HRT, hormone replacement therapy. * , p   0.05; * * , p   
0.01; * * * , p   0.001 vs. pretreatment values; #, p   0.05 DHEA or HRT vs. vitamin D 
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10. CONCLUSION AND PROSPECTIVES 
Over the past 10 years, hormone preparations of dehydroepiandrosterone (DHEA) have been 
available over the counter and have been sold as the ‘fountain of youth’. This has raised concerns 
about the real clinical efficacy and the possible effects of such uncontrolled and widespread 
hormonal self-administration and the lack of quality control in this increasingly financially 
rewarding business. 
Upcoming experimental and clinical studies renew the attention and the debate on one of the most 
attractive and controversial issues in the physiology of the aging process that is still far from being 
clearly defined by the scientific community. 
The most relevant aspect meriting attention is certainly the controversial finding among the studies 
that investigate the correlation of the endogenous DHEA sulfate (DHEAS) level, the aging process 
or organ illness with the results coming from studies focusing on the effects of exogenous DHEAS 
administration on brain function, sexuality, cardiovascular health and metabolic syndrome. 
Indeed, the marked age-related decline in serum DHEA and DHEAS has suggested that a 
deficiency of these steroids may be causally related to the development of a series of diseases that 
are generally associated with aging. 
The postulated consequences of low DHEA levels include insulin resistance, obesity, 
cardiovascular disease, cancer, reduction of the immune defense system as well as psychosocial 
problems such as depression and a general deterioration in the sensation of well-being and cognitive 
function. 
There is also growing evidence in the literature that a low DHEAS level, representing the most 
abundant sex steroids in plasma in humans (more than 1000 times higher than estradiol and 
testosterone levels), negatively correlates with the domains of sexual function in pre and 
postmenopausal women to a greater extent than testosterone levels. Nonetheless, a DHEAS cut-off 
level for defining androgen deficiency syndrome has not been established. Similarly, in a cross-
sectional study, higher endogenous DHEAS levels are independently and favorably associated with 
several measures of cognitive function and well-being. As a consequence, DHEA replacement may 
seem an attractive treatment opportunity. Nevertheless, the analyses of clinical outcomes are far 
from being conclusive and many issues should still be addressed. Although DHEA preparations 
have been available in the market since the 1990s, there are very few definitive reports on the 
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biological functions of this steroid, and it is still the case that its regulation is unclear and its 
mechanisms of action largely yet to be established.  
The great conundrum in this area is the lack of a clear mechanism of action of DHEA. It is known 
that this steroid serves as a precursor for estrogens and androgens, and many believe that DHEA is 
merely an inactive precursor pool for the formation of bioactive steroid hormones. To this extent, 
oral supplementation of DHEA in postmenopausal women results in the formation of significant 
amounts of 17b-estradiol and estrone, accompanied by increases in androstenedione, testosterone 
and dihydrotestosterone. This, plus the evidence that DHEA can also be converted into estrogens 
and other androgens within cells, supports the view that many actions of this steroid are indirect and 
mediated via estrogen and/or androgen receptors. However, the rate of DHEA metabolism into 
estrogen/testosterone in different tissues, the presence of enzyme regulators and the effect of the 
aging process on the intracrinology of DHEA require additional investigation. Indeed, DHEA 
administration in both early and late postmenopausal women directly affects the agerelated changes 
in adrenal enzymatic pathways and steroid synthesis, including DHEA and progesterone. 
There is, also, increasing evidence for DHEA acting in its own right through a dedicated, although 
as yet unidentified, receptor. The existence of such a receptor for DHEA has been particularly 
investigated in brain tissue and in vascular cells.  
Although there is still debate on DHEA receptors, these findings corroborate the evidence that 
DHEA is not just a pre-hormone of the adrenals, but rather a hormone in its own right, and that it 
modulates a series of biological processes, with a remarkable tropism for the central nervous system. 
Clinically, the spectrum of women that would benefit from DHEA therapy is not clearly defined 
and nor is the dosage of hormone treatment. Whether DHEA therapy could be prescribed as a 
general anti-aging therapy or could be an alternative treatment for women suffering from androgen 
deficiency syndrome remains uncertain across studies. In particular, among symptomatic women, 
the spectrum of symptoms responding to DHEA requires further investigation, to define the type of 
sexual symptoms (e.g. decreased sexual function or hypoactive sexual desire disorder) and the 
degree of mood/cognitive symptoms that could be responsive to hormonal treatment. 
Similarly, the definition of criteria for the choice of the starting dosage of DHEA to be prescribed in 
postmenopausal women needs further investigation: the extent of the symptoms, baseline DHEA(S) 
plasma levels, concomitant estrogen therapy or the combination of all the previous should be 
considered. 
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Plasma DHEA(S) levels at baseline and during treatment merit attention given that a cut-off value 
for DHEA(S) deficiency is not yet defined and the plasma level might not represent the rate of 
tissue conversion into estrogens or delta-4 androgens. This fact is also coupled with the route of 
administration of DHEA, given that oral, vaginal and parenteral administrations seem to induce 
different steroid concentrations in the plasma, with different clinical consequences and applications. 
All these findings may have far-reaching implications in the debate about the role of DHEA(S) in 
the female aging process and might reconcile discordant findings from basic science and clinical 
studies. 
The lack of definitive evidence for biological mechanisms and the presence of only a few studies 
that address these emerging issues of DHEA therapy in postmenopausal women might encourage a 
new critical analysis of the available literature, evidencing current limits and incongruities. 
Concurrently, new clinical trials, specifically planned to relate to the biology of symptomatic 
postmenopausal women and designed for the translation of basic science into clinical practice, are 
now a required step to move forward the scientific debate on DHEA. 
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